{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:04:00Z","timestamp":1790996640720,"version":"4.1.0"},"reference-count":733,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.pharmthera.2010.06.002","type":"journal-article","created":{"date-parts":[[2010,7,2]],"date-time":"2010-07-02T08:24:10Z","timestamp":1278059050000},"page":"229-273","source":"Crossref","is-referenced-by-count":86,"title":["From the cell to the clinic: A comparative review of the partial D2\/D3 receptor agonist and \u03b12-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease"],"prefix":"10.1016","volume":"128","author":[{"given":"Mark J.","family":"Millan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2010.06.002_bb0005","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/jnnp.2005.083113","article-title":"Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress","volume":"78","author":"Aarsland","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0010","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0014-2999(94)90013-2","article-title":"The potent and selective dopamine D1 receptor agonist A-77636 increases cortical and hippocampal acetylcholine release in the rat","volume":"260","author":"Acquas","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0015","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1002\/mds.870040514","article-title":"Biochemistry of Parkinson's disease 28years later: a critical review","volume":"4","author":"Agid","year":"1989","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0020","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1081\/RRS-200029953","article-title":"Signaling mechanisms of the D3 dopamine receptor","volume":"24","author":"Ahlgren-Beckendorf","year":"2004","journal-title":"J Recept Signal Transduct"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0025","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1212\/WNL.0b013e3181d7d8e2","article-title":"Rasagiline, Parkinson-neuroprotection, and delayed-start trials: still no satisfaction?","volume":"74","author":"Ahlskog","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0030","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.neulet.2005.10.069","article-title":"Alpha2-adrenoceptor-mediated modulation of the release of GABA and noradrenaline in the rat substantia nigra pars reticulata","volume":"395","author":"Alachkar","year":"2006","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0035","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.taap.2009.07.010","article-title":"Effects of glutamate and Alpha2-noradrenergic receptor antagonists on the development of neurotoxicity produced by chronic rotenone in rats","volume":"240","author":"Alam","year":"2009","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0040","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1093\/brain\/awn238","article-title":"Bilateral subthalamic stimulation impairs cognitive-motor performance in Parkinson's disease patients","volume":"131","author":"Alberts","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0045","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/mds.20237","article-title":"Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease","volume":"19","author":"Alegret","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0050","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/j.1460-9568.1995.tb01085.x","article-title":"Complex deficits on reaction time performance following bilateral intrastriatal 6-OHDA infusion in the rat","volume":"7","author":"Amalric","year":"1995","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0055","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.pharmthera.2004.12.004","article-title":"Cocaine-induced alterations in dopamine receptor signalling: implications for reinforcement and reinstatement","volume":"106","author":"Anderson","year":"2005","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0060","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.pbb.2004.11.015","article-title":"Effects of clomipramine on self-control choice in Lewis and Fischer 344 rats","volume":"80","author":"Anderson","year":"2005","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0065","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1586\/ern.09.48","article-title":"Apomorphine and Levo-Dopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management","volume":"9","author":"Antonini","year":"2009","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0070","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1527-3458.2001.tb00198.x","article-title":"A review of the pharmacological and clinical profile of mirtazapine","volume":"7","author":"Anttila","year":"2001","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0075","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s007020070039","article-title":"Sequential changes of cholinergic and dopaminergic receptors in brains after 6-hydroxydopamine lesions of the medial forebrain bundle in rats","volume":"107","author":"Araki","year":"2000","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0080","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0924-977X(00)00094-8","article-title":"Temporal changes of dopaminergic and glutamatergic receptors in 6-hydroxydopamine-treated rat brain","volume":"10","author":"Araki","year":"2000","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0085","first-page":"S1","article-title":"Piribedil improves apathy, depression and anxiety in Parkinson's disease","volume":"24","author":"Ardouin","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0090","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0014-2999(96)00142-2","article-title":"Dopamine autoreceptor reserve in vitro: possible role of dopamine D3 receptors","volume":"305","author":"Aretha","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0095","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nrn2648","article-title":"Stress signalling pathways that impair prefrontal cortex structure and function","volume":"10","author":"Arnsten","year":"2009","journal-title":"Nat Rev"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0100","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.biopsych.2004.08.019","article-title":"Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions","volume":"57","author":"Arnsten","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0105","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1136\/jnnp.65.2.155","article-title":"Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study","volume":"65","author":"Asahina","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0110","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/978-3-211-45295-0_37","article-title":"Neuroimaging in Parkinson's disease","volume":"70","author":"Au","year":"2006","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0115","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0898-6568(02)00030-X","article-title":"Ligand modulation of [35S]GTPgammaS binding at human alpha(2A), alpha(2B) and alpha(2C) adrenoceptors","volume":"14","author":"Audinot","year":"2002","journal-title":"Cell Signal"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0120","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00001756-200201210-00039","article-title":"A dopamine D3 receptor partial agonist blocks the expression of conditioned activity","volume":"13","author":"Aujla","year":"2002","journal-title":"NeuroReport"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0125","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0165-1781(00)00222-5","article-title":"Effect of apomorphine on motor and cognitive function in melancholic patients: a preliminary report","volume":"97","author":"Austin","year":"2000","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0130","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0893-133X(00)00111-1","article-title":"The \u03b12A-adrenoceptor agonist, guanfacine, increases regional cerebral blood flow in dorsolateral prefrontal cortex of monkeys performing a spatial working memory task","volume":"23","author":"Avery","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0135","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.parkreldis.2008.07.004","article-title":"Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis","volume":"15","author":"Baker","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0140","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2165\/00023210-200721120-00007","article-title":"Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease","volume":"21","author":"Baldwin","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0145","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/mds.20370","article-title":"Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease","volume":"20","author":"Bara-Jimenez","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0150","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1037\/a0014625","article-title":"Dopamine modulates effort-based decision making in rats","volume":"123","author":"Bardgett","year":"2009","journal-title":"Behav Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0155","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1523\/JNEUROSCI.5289-06.2007","article-title":"Recognition memory for objects, place, and temporal order: a disconnection analysis of the role of the medial prefrontal cortex and perirhinal cortex","volume":"27","author":"Barker","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0160","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/WNL.53.3.573","article-title":"Pergolide monotherapy in the treatment of early PD: a randomized, controlled study","volume":"53","author":"Barone","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0165","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00415-006-0067-5","article-title":"Depression\/Parkinson Italian Study Group. Pramipexole vs sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study","volume":"253","author":"Barone","year":"2006","journal-title":"J Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0170","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/0269881103017001688","article-title":"The modulatory effects of dopamine D1 and D2 receptor function on object working memory in humans","volume":"17","author":"Bartholomeusz","year":"2003","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0175","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/sj.npp.1300677","article-title":"Antidepressant-like effect of D2\/3 receptor-, but not D4 receptor-activation in the rat forced swim test","volume":"30","author":"Basso","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0180","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0306-4522(02)00757-1","article-title":"Effects of the alpha2-adrenoceptor antagonist dexefaroxan on neurogenesis in the olfactory bulb of the adult rat in vivo: selective protection against neuronal death","volume":"117","author":"Bauer","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0185","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bandc.2008.03.008","article-title":"Neural substrates of cognitive skill learning in Parkinson's disease","volume":"68","author":"Beauchamp","year":"2008","journal-title":"Brain Cogn"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0190","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.cell.2005.05.012","article-title":"An Akt\/\u03b2-arrestin 2\/PP2A signaling complex mediates dopaminergic neurotransmission and behavior","volume":"122","author":"Beaulieu","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0195","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1523\/JNEUROSCI.5074-06.2007","article-title":"Regulation of Akt signalling by D2 and D3 dopamine receptors in vivo","volume":"27","author":"Beaulieu","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0200","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1471-4159.2008.05406.x","article-title":"Alpha-synuclein aggregation and cell death triggered by energy deprivation on dopamine overload are counteracted by D2\/D3 receptor activation","volume":"106","author":"Bellucci","year":"2008","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0205","doi-asserted-by":"crossref","first-page":"9595","DOI":"10.1523\/JNEUROSCI.2583-07.2007","article-title":"Noradrenergic modulation of subthalamic nucleus activity: behavioral and electrophysiological evidence in intact and 6-hydroxydopamine-lesioned rats","volume":"27","author":"Belujon","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0210","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1474-4422(08)70291-6","article-title":"Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease","volume":"8","author":"Benabid","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0215","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1210\/er.22.6.724","article-title":"Dopamine as a prolactin (PRL) inhibitor","volume":"22","author":"Ben-Jonathan","year":"2001","journal-title":"Endocr Rev"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0220","doi-asserted-by":"crossref","first-page":"28304","DOI":"10.1074\/jbc.M403899200","article-title":"Comparative studies of molecular mechanisms of dopamine D2 and D3 receptors for the activation of extracellular signal-regulated kinase","volume":"279","author":"Beom","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0225","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0165-0173(03)00143-7","article-title":"The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes","volume":"42","author":"Berridge","year":"2003","journal-title":"Brain Res Rev"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0230","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S1353-8020(09)70827-2","article-title":"Dopamine receptors and L-dopa-induced dyskinesia","volume":"15","author":"Berthet","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0235","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/S0278-5846(99)00067-6","article-title":"Effect of the \u03b12-adrenoreceptor antagonist, idazoxan, on motor disabilities in MPTP-treated monkeys","volume":"23","author":"B\u00e9zard","year":"1999","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0240","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nm875","article-title":"Attenuation of Levo-Dopa-induced dyskinesia by normalizing dopamine D3 receptor function","volume":"9","author":"B\u00e9zard","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0245","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/mds.20764","article-title":"Rasagiline improves quality of life in patients with early Parkinson's disease","volume":"21","author":"Biglan","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0250","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/jnr.21978","article-title":"Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats","volume":"87","author":"Bishop","year":"2009","journal-title":"J Neurosci Res"},{"issue":"Suppl","key":"10.1016\/j.pharmthera.2010.06.002_bb0255","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s00415-008-5005-2","article-title":"Genes associated with Parkinson syndrome","volume":"255","author":"Biskup","year":"2008","journal-title":"J Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0260","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0306-4522(98)00306-6","article-title":"Alpha2C-adrenoceptor overexpression disrupts execution of spatial and non-spatial search patterns","volume":"88","author":"Bjorklund","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0265","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0306-4522(99)00428-5","article-title":"Overexpression of \u03b12C-adrenoceptors impairs water maze navigation","volume":"95","author":"Bjorklund","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0270","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ddstr.2004.08.002","article-title":"Serotonergic agents and Parkinson's disease","volume":"1","author":"Blackburn","year":"2004","journal-title":"Drug Discov Today Ther Strateg"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3665","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1016\/j.parkreldis.2008.04.015","article-title":"The 6-hydroxydopamine model: news from the past","volume":"14","author":"Blandini","year":"2008","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0275","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s00415-005-0971-0","article-title":"Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia","volume":"253","author":"Bohnen","year":"2006","journal-title":"J Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0280","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1124\/mol.106.027763","article-title":"D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinase 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism","volume":"71","author":"Bolan","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0285","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/00146965-200312000-00001","article-title":"A review of the cognitive and behavioral sequelae of Parkinson's disease: relationship to frontostriatal circuitry","volume":"16","author":"Borod","year":"2003","journal-title":"Cogn Behav Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0290","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00702-008-0132-6","article-title":"MEG resting state functional connectivity in Parkinson's disease related dementia","volume":"116","author":"Bosboom","year":"2009","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0295","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.tins.2006.01.002","article-title":"Dopamine in neurotoxicity and neuroprotection: what do D2 receptors have to do with it?","volume":"29","author":"Bozzi","year":"2006","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0300","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson's disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0305","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/00023210-200418110-00003","article-title":"PKDS009 Study Group. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, LEVO-DOPA-controlled study","volume":"18","author":"Bracco","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0310","doi-asserted-by":"crossref","first-page":"8911","DOI":"10.1523\/JNEUROSCI.22-20-08911.2002","article-title":"Dopamine induces a PI3-kinase-independent activation of Akt in striatal neurons: a new route to cAMP response element-binding protein phosphorylation","volume":"22","author":"Brami-Cherrier","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0315","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.euroneuro.2009.11.012","article-title":"(+)-UH 232, a partial agonist at D3 dopamine receptors, attenuates cognitive effects of angiotensin IV and des-Phe(6)-angiotensin IV in rats","volume":"20","author":"Braszko","year":"2010","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0320","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/mds.870080214","article-title":"Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980","volume":"8","author":"Bravi","year":"1993","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0325","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/00023210-199810030-00004","article-title":"\u03b12-Adrenoceptor antagonists: a new approach to Parkinson's disease?","volume":"10","author":"Brefel-Courbon","year":"1998","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0330","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/01.fbp.0000236267.41806.5b","article-title":"Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors","volume":"17","author":"Brocco","year":"2006","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0335","first-page":"115","article-title":"The \u03b12-adrenoceptor antagonist, atipamezole, facilitates actions of the D2\/D3 agonist, quinpirole, in models of antiparkinsonian and antidepressant activity","volume":"13","author":"Brocco","year":"2001","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0340","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.biopsych.2005.12.017","article-title":"Imaging in Parkinson's disease: the role of monoamines in behavior","volume":"59","author":"Brooks","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0345","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/mds.20612","article-title":"Nondopaminergic mechanisms in Levodopa-induced dyskinesia","volume":"20","author":"Brotchie","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0350","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/35049064","article-title":"Recognition memory: what are the roles of the perirhinal cortex and hippocampus?","volume":"2","author":"Brown","year":"2001","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0355","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1136\/jnnp.2003.031237","article-title":"Hippocampal and prefrontal atrophy in patients with early non-demented Parkinson's disease is related to cognitive impairment","volume":"75","author":"Br\u00fcck","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0360","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s007020200040","article-title":"A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa","volume":"109","author":"Brunt","year":"2002","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0365","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1007\/s00702-002-0811-7","article-title":"Pramipexole in comparison to L-dopa: a neuropsychological study","volume":"110","author":"Brusa","year":"2003","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0370","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00702-004-0193-0","article-title":"Pergolide effect on cognitive functions in early-mild Parkinson's disease","volume":"112","author":"Brusa","year":"2005","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0375","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.pharmthera.2007.02.002","article-title":"Inhibition of MAPK and stimulation of AKT kinase signaling pathways: two approaches with therapeutic potential in the treatment of neurodegenerative disease","volume":"114","author":"Burke","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0380","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/j.1471-4159.2007.05106.x","article-title":"Programmed cell death and new discoveries in the genetics of parkinsonism","volume":"104","author":"Burke","year":"2008","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0385","first-page":"307","article-title":"Apomorphine and piribedil in rats: biochemical and pharmacologic studies","volume":"9","author":"Butterworth","year":"1975","journal-title":"Adv Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0390","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1124\/jpet.102.036673","article-title":"Increased dopamine receptor signaling and dopamine receptor-G protein coupling in denervated striatum","volume":"302","author":"Cai","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0395","doi-asserted-by":"crossref","first-page":"S259","DOI":"10.1016\/S1353-8020(08)70013-0","article-title":"Neuronal networks and synaptic plasticity in Parkinson's disease: beyond motor deficits","volume":"13","author":"Calabresi","year":"2007","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0400","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000119302","article-title":"The dopamine agonists lisuride and piribedil protect against behavioural and histological changes following 4-vessel occlusion in the rat","volume":"34","author":"Caldwell","year":"1996","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0405","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1600-0404.1975.tb05772.x","article-title":"Piribedil (ET 495) in the treatment of Parkinson's disease combined with amantadine or levodopa","volume":"52","author":"Callaghan","year":"1975","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0410","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00213-002-1247-3","article-title":"Local injections of the 5-hydroxytryptamine antagonist mianserin into substantia nigra pars reticulata block tremulous jaw movements in rats: studies with a putative model of Parkinsonian tremor","volume":"165","author":"Carlson","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0415","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s100720170046","article-title":"Alterations in GAD67, dynorphin and enkephalin mRNA in striatal output neurons following priming in the 6-OHDA model of Parkinson's disease","volume":"22","author":"Carta","year":"2001","journal-title":"Neurol Sci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0420","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/syn.20527","article-title":"Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat","volume":"62","author":"Carta","year":"2008","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0425","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1471-4159.2009.06425.x","article-title":"Inactivation of neuronal forebrain A2A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease","volume":"111","author":"Carta","year":"2009","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0430","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1353-8020(00)00061-4","article-title":"Neuroprotective effects of D3 dopamine receptor agonists","volume":"7","author":"Carvey","year":"2001","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0435","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/da.20038","article-title":"Pramipexole in treatment-resistant depression: an extended follow-up","volume":"20","author":"Cassano","year":"2004","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0440","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1007\/s00415-006-0510-7","article-title":"Apathy and verbal fluency in STN-stimulated PD patients. An observational follow-up study","volume":"254","author":"Castelli","year":"2007","journal-title":"J Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0445","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.parkreldis.2009.08.010","article-title":"Neuropsychological changes 1-year after subthalamic DBS in PD patients: a prospective controlled study","volume":"16","author":"Castelli","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0450","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/mds.20750","article-title":"A 1-year randomized, double-blind trial comparing piribedil (150mg\/day) with bromocriptine (25mg\/day) in early combination with Levodopa in Parkinson's disease","volume":"21","author":"Castro-Caldas","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0455","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1471-4159.2006.04124.x","article-title":"Post-versus presynaptic plasticity in L-DOPA-induced dyskinesia","volume":"99","author":"Cenci","year":"2006","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0460","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/sj.npp.1300169","article-title":"Cocaine-seeking behavior in response to drug-associated stimuli in rats: involvement of D3 and D2 dopamine receptors","volume":"28","author":"Cervo","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0465","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/cne.902870308","article-title":"Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression","volume":"287","author":"Chan-Palay","year":"1989","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0470","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1096\/fj.04-1551fje","article-title":"Glycogen synthase kinase 3\u03b2 (GSK3\u03b2) mediates 6-hydroxydopamine-induced neuronal death","volume":"18","author":"Chen","year":"2004","journal-title":"FASEB J"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0475","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.febslet.2008.01.028","article-title":"D2\/D3 receptor agonist ropinirole protects dopaminergic cell line against rotenone-induced apoptosis through inhibition of caspase- and JNK-dependent pathways","volume":"582","author":"Chen","year":"2008","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0480","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.bcp.2008.04.010","article-title":"GSK3\u03b2 and endoplasmic reticulum stress mediate rotenone-induced death of SK-N-MC neuroblastoma cells","volume":"76","author":"Chen","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0485","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.bbrc.2006.09.090","article-title":"Characterization of the desensitization properties of five dopamine receptor subtypes and alternatively spliced variants of dopamine D2 and D4 receptors","volume":"350","author":"Cho","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0490","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1006\/bbrc.1999.0286","article-title":"G protein-mediated mitogen-activated protein kinase activation by two dopamine D2 receptors","volume":"256","author":"Choi","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0495","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1471-4159.2009.06463.x","article-title":"A novel mTOR activating protein protects dopamine neurons against oxidative stress by repressing autophagy related cell death","volume":"112","author":"Choi","year":"2010","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0500","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S0022-3565(24)38022-X","article-title":"Effects of alpha2-adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway","volume":"288","author":"Chopin","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0505","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1124\/jpet.301.1.187","article-title":"Effects of acute and subchronic administration of dexefaroxan, an alpha(2)-adrenoceptor antagonist, on memory performance in young adult and aged rodents","volume":"301","author":"Chopin","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0510","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.biopsycho.2006.01.005","article-title":"Functions of frontostriatal systems in cognition: comparative neuropsychopharmacological studies in rats, monkeys and humans","volume":"73","author":"Chudasama","year":"2006","journal-title":"Biol Psychol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0515","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/mds.21771","article-title":"Tremor dominant Parkinsonism: clinical description and LRRK2 mutation screening","volume":"23","author":"Clarimon","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0520","first-page":"CD001519","article-title":"Cabergoline versus bromocriptine for Levo-Dopa-induced complications in Parkinson's disease","volume":"1","author":"Clarke","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0525","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0140-6736(02)11668-0","article-title":"Dopamine agonist monotherapy in Parkinson's disease","volume":"360","author":"Clarke","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0530","first-page":"CD002259","article-title":"Pramipexole versus bromocriptine for Levodopa-induced complications in Parkinson's disease","volume":"3","author":"Clarke","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0535","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.parkreldis.2009.09.005","article-title":"Systematic review of apomorphine infusion, Levodopa infusion and deep brain stimulation in advanced Parkinson's disease","volume":"15","author":"Clarke","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0540","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/sj.bjp.0702673","article-title":"Comparison of the functional potencies of ropinirole and other dopamine receptor agonists in human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells","volume":"127","author":"Coldwell","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0545","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/j.1460-9568.2008.06423.x","article-title":"Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation","volume":"28","author":"Collo","year":"2008","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0550","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neubiorev.2005.03.024","article-title":"Dopaminergic modulation of cognitive function-implications for L-Dopa treatment in Parkinson's disease","volume":"30","author":"Cools","year":"2006","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0555","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.neuropsychologia.2006.03.030","article-title":"Reversal learning in Parkinson's disease depends on medication status and outcome valence","volume":"44","author":"Cools","year":"2006","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0560","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1523\/JNEUROSCI.4467-08.2009","article-title":"Striatal dopamine predicts outcome-specific reversal learning and its sensitivity to dopaminergic drug administration","volume":"29","author":"Cools","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0565","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/sj.npp.1301153","article-title":"L-dopa disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease","volume":"32","author":"Cools","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0570","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1212\/01.WNL.0000158652.74601.48","article-title":"Nocturnal activity with night-time pergolide in Parkinson disease: a controlled study using actigraphy","volume":"64","author":"Cornella","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0575","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/(SICI)1520-6394(2000)11:2<58::AID-DA2>3.0.CO;2-H","article-title":"Comparison of pramipexole, fluoxetine and placebo in patients with major depression","volume":"11","author":"Corrigan","year":"2000","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0580","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1155\/2008\/310437","article-title":"Dopaminergic modulation of prospective memory in Parkinson's disease","volume":"19","author":"Costa","year":"2008","journal-title":"Behav Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0585","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.neuropsychologia.2009.01.039","article-title":"Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory","volume":"47","author":"Costa","year":"2009","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0590","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1358\/dnp.2001.14.1.858386","article-title":"Modulation of attention by noradrenergic \u03b12-agents varies according to arousal level","volume":"14","author":"Coull","year":"2001","journal-title":"Drug News Perspect"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0595","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/BF02311179","article-title":"Contrasting effects of clonidine and diazepam on tests of working memory and planning","volume":"120","author":"Coull","year":"1995","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0600","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF02246578","article-title":"The \u03b12 antagonist idazoxan remediates certain attentional and executive dysfunction in patients with dementia of the frontal type","volume":"123","author":"Coull","year":"1996","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0605","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1111\/j.1460-9568.2005.04015.x","article-title":"Selective effects of partial striatal 6-OHDA lesions on information processing in the rat","volume":"21","author":"Courtiere","year":"2005","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0610","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jneumeth.2009.03.007","article-title":"Anxiolytics antagonize yohimbine-induced central noradrenergic activity: a concomitant in vivo voltammetry-electrophysiology model of anxiety","volume":"180","author":"Crespi","year":"2009","journal-title":"J Neurosci Meth"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0615","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.biopsych.2006.03.004","article-title":"Molecular imaging of the dopaminergic system and its association with human cognitive function","volume":"59","author":"Cropley","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0620","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1124\/mol.56.5.1025","article-title":"Human dopamine D3 receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase C-dependent mechanism","volume":"56","author":"Cussac","year":"1999","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0625","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/mds.21949","article-title":"Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom","volume":"23","author":"Czernecki","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0630","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.neubiorev.2004.09.006","article-title":"Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates","volume":"28","author":"Dalley","year":"2004","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0635","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/brain\/122.8.1437","article-title":"The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease","volume":"122","author":"Damier","year":"1999","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0640","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/0306-4522(93)90235-8","article-title":"Dopaminergic regulation of cortical acetylcholine release: effects of dopamine receptor agonists","volume":"54","author":"Day","year":"1993","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0645","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson's disease","volume":"5","author":"De Lau","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0650","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1530\/acta.0.1040385","article-title":"Differential effects of a dopaminergic drug (piribedil) on pituitary hormone release in normal men and women","volume":"104","author":"De Marinis","year":"1983","journal-title":"Acta Endocrinol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0655","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.coph.2008.12.002","article-title":"Getting specialized: presynaptic and postsynaptic dopamine D2 receptors","volume":"9","author":"De Mei","year":"2009","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0660","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/BF00973098","article-title":"\u03b12-Adrenoceptor mediated inhibition of [3H]dopamine release from nucleus accumbens slices and monoamine levels in a rat model for attention-deficit hyperactivity disorder","volume":"20","author":"De Villiers","year":"1995","journal-title":"Neurochem Res"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0665","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0306-4522(02)00406-2","article-title":"Protective effects of the alpha2-adrenoceptor antagonist, dexefaroxan, against degeneration of the basalocortical cholinergic system induced by cortical devascularization in the adult rat","volume":"115","author":"Debeir","year":"2002","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0670","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.expneurol.2004.08.023","article-title":"In vivo upregulation of endogenous NGF in the rat brain by the alpha2-adrenoceptor antagonist dexefaroxan: potential role in the protection of the basalocortical cholinergic system during neurodegeneration","volume":"190","author":"Debeir","year":"2004","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0675","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/j.1460-9568.2004.03586.x","article-title":"Attention and executive function deficits in chronic low-dose MPTP-treated non-human primates","volume":"20","author":"Decamp","year":"2004","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0680","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.brainres.2009.01.028","article-title":"Interaction between nicotinic and dopaminergic therapies on cognition in a chronic Parkinson model","volume":"1262","author":"Decamp","year":"2009","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0685","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.neuropharm.2006.05.012","article-title":"Discriminative stimulus properties of the selective and highly potent \u03b12-adrenoceptor agonist, S18616, in rats: mediation by the \u03b12A subtype, and blockade by the atypical antidepressants, mirtazapine and mianserin","volume":"51","author":"Dekeyne","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0690","unstructured":"Dekeyne, A., Loiseau, F., Watson, D., Fone, K., & Millan, M.J. (2009). S32212, a potential antidepressant with antagonist properties at 5-HT2A, 5-HT2C and \u03b12-adrenergic receptors: pro-cognitive actions in rats. SFN Abstract; 444.15."},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0695","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.neubiorev.2007.01.005","article-title":"The pharmacology, neuroanatomy and neurogenetics on one-trial object recognition in rodents","volume":"31","author":"Dere","year":"2007","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0700","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000104877","article-title":"Effect of addition of yohimbine (alpha-2-receptor antagonist) to the antidepressant activity of fluoxetine or venlafaxine in the mouse forced swim test","volume":"80","author":"Dhir","year":"2007","journal-title":"Pharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0705","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1017\/S1461145706007103","article-title":"Activation of dopamine D1 receptors enhances cholinergic transmission and social cognition: a parallel dialysis and behavioural study in rats","volume":"10","author":"Di Cara","year":"2007","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0710","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/jnnp.2005.065334","article-title":"The effect of deep brain stimulation on quality of life in movement disorders","volume":"76","author":"Diamond","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0715","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/mds.22172","article-title":"Lesions outside the CNS in Parkinson's disease","volume":"24","author":"Djaldetti","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0720","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0072-9752(07)83016-8","article-title":"Sensory symptoms in Parkinson's disease","volume":"83","author":"Djaldetti","year":"2007","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3670","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/archneur.62.9.noc50009","article-title":"Pathological gambling caused by drugs used to treat Parkinson disease","volume":"62","author":"Dodd","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0725","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1212\/01.WNL.0000031424.51127.2B","article-title":"Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study","volume":"60","author":"Doder","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0730","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1254\/jjp.77.227","article-title":"Effects of talipexole on contraversive rotation and functional impairment in MPTP-induced chronic hemiparkinsonian monkeys","volume":"77","author":"Domino","year":"1998","journal-title":"Jpn J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0735","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0278-5846(83)90085-4","article-title":"Piribedil: behavioral, neurochemical and clinical profile of a dopamine agonist","volume":"7","author":"Dourish","year":"1983","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0740","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s00415-006-0177-0","article-title":"Does subthalamic nucleus stimulation induce apathy in Parkinson's disease?","volume":"253","author":"Drapier","year":"2006","journal-title":"J Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0745","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/j.neuropsychologia.2008.05.006","article-title":"Emotion recognition impairment and apathy after subthalamic nucleus stimulation in Parkinson's disease have separate neural substrates","volume":"46","author":"Drapier","year":"2008","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0750","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1111\/j.1460-9568.2005.04438.x","article-title":"Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons","volume":"22","author":"Du","year":"2005","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0755","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1038\/sj.npp.1300276","article-title":"Effects of a dopamine D3 receptor ligand, BP897, on acquisition and expression of food-, morphine-, and cocaine-induced conditioned place preference, and food-seeking behavior in rats","volume":"28","author":"Duarte","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0760","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/PL00007725","article-title":"Cognitive deficits in Parkinson's disease","volume":"244","author":"Dubois","year":"1997","journal-title":"J Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0765","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.neuropharm.2008.08.031","article-title":"Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat","volume":"55","author":"Dupre","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0770","first-page":"S206","article-title":"Orodispersible piribedil (S90049), a non-ergot dopamine agonist, decreases the time to ON and prolongs the ON duration in a dose-dependent manner in combination with Levodopa","volume":"23","author":"Durif","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0775","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0278-5846(01)00321-9","article-title":"Effects of aging on prefrontal temporal cortical network function in healthy volunteers as assessed by COWA: an exploratory survey","volume":"26","author":"Dursun","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0780","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0014-2999(88)90096-9","article-title":"Acute effects of direct dopamine agonists in the mouse behavioral despair test","volume":"154","author":"Duterte-Boucher","year":"1988","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0785","doi-asserted-by":"crossref","first-page":"10577","DOI":"10.1523\/JNEUROSCI.1767-06.2006","article-title":"Dopaminergic control of sleep\u2013wake states","volume":"26","author":"Dzirasa","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0790","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s002130050585","article-title":"Agonist activity of LSD and lisuride at cloned 5-HT2A and 5-HT2C receptors","volume":"136","author":"Egan","year":"1998","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0795","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00004691-199603000-00004","article-title":"Central mechanisms of tremor","volume":"13","author":"Elble","year":"1996","journal-title":"J Clin Neurophysiol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0800","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1515\/REVNEURO.2007.18.1.37","article-title":"Insights into the role of dopamine receptor systems in learning and memory","volume":"18","author":"El-Ghundi","year":"2007","journal-title":"Rev Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0805","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1017\/S1461145705005407","article-title":"Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans","volume":"9","author":"Ellis","year":"2006","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0810","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/mds.21507","article-title":"Clinical diagnostic criteria for dementia associated with Parkinson's disease","volume":"22","author":"Emre","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0815","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbi.2009.01.018","article-title":"Time-dependent alterations of peripheral immune parameters after nigrostriatal dopamine depletion in a rat model of Parkinson's disease","volume":"23","author":"Engler","year":"2009","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0820","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/syn.20630","article-title":"The role of the dorsal raphe nucleus in the development, expression, and treatment of L-Dopa-induced dyskinesia in hemiparkinsonian rats","volume":"63","author":"Eskow","year":"2009","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0825","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1353-8020(03)00096-8","article-title":"Piribedil as an adjunct to Levodopa in advanced Parkinson's disease: the Asian experience","volume":"10","author":"Evidente","year":"2003","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0830","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1002\/mds.22709","article-title":"Brain dopaminergic modulation associated with executive function in Parkinson's disease","volume":"24","author":"Farid","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0835","first-page":"S101","article-title":"Safety and efficacy of piribedil as adjunctive treatment for Parkinson's disease: six-month placebo-controlled study","volume":"17","author":"Fedorova","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0840","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0197-0186(02)00049-9","article-title":"Noradrenergic regulation of inflammatory gene expression in brain","volume":"41","author":"Feinstein","year":"2002","journal-title":"Neurochem Int"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0845","first-page":"1","article-title":"Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signalling","volume":"53","author":"Ferguson","year":"2001","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0850","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/BF02245694","article-title":"Behavioural evidence that different neurochemical mechanisms underlie stretching\u2013yawning and penile erection induced in male rats by SND 919, a new selective D2 dopamine receptor agonist","volume":"113","author":"Ferrari","year":"1993","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0855","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/brain\/awp229","article-title":"Effects of peduncolopontine nucleus area stimulation on gait disorders in Parkinson's disease","volume":"133","author":"Ferraye","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0860","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/S0140-6736(00)02119-X","article-title":"Sleep attacks and Parkinson's disease treatment","volume":"355","author":"Ferreira","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0865","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pneurobio.2009.02.004","article-title":"Early involvement of the cerebral cortex in Parkinson's disease: convergence of multiple metabolic defects","volume":"88","author":"Ferrer","year":"2009","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0870","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0364-7722(81)90076-X","article-title":"Effects of a piperazine derivative, piribedil, on exploration, locomotor activity and social behaviour in the rat","volume":"5","author":"File","year":"1981","journal-title":"Prog Neuropsychopharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0875","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1124\/mol.107.043885","article-title":"Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization","volume":"74","author":"Fiorentini","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0880","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/0269216307087148","article-title":"Prolactin and dopamine: what is the connection? A review article","volume":"22","author":"Fitzgerald","year":"2008","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0885","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0091-3057(88)90032-9","article-title":"Memory enhancement in mice: role of drug dose and training\u2013testing interval","volume":"29","author":"Flood","year":"1988","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0890","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00213-006-0404-5","article-title":"Mesocortical dopamine modulation of executive functions: beyond working memory","volume":"188","author":"Floresco","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0895","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1046\/j.1460-9568.2003.02510.x","article-title":"\u03b12A and \u03b12C-adrenoceptor regulation in the brain: \u03b12A changes persist after chronic stress","volume":"17","author":"Fl\u00fcgge","year":"2003","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0900","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00702-003-0059-x","article-title":"Dopamine receptor agonists in the therapy of Parkinson's disease","volume":"111","author":"Foley","year":"2004","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0905","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.2174\/092986707781745550","article-title":"Noradrenaline in Parkinson's disease: from disease progression to current therapeutics","volume":"14","author":"Fornai","year":"2007","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0910","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0079-6123(08)00923-0","article-title":"Parkinson's disease opportunities for novel therapeutics to reduce the problems of Levodopa therapy","volume":"172","author":"Fox","year":"2008","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0915","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/mds.20936","article-title":"Translation of nondopaminergic treatments for Levodopa-induced dyskinesia from MPTP-lesioned non-human primates to Phase ll a clinical studies; keys to success and roads to failure","volume":"21","author":"Fox","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0920","doi-asserted-by":"crossref","first-page":"S351","DOI":"10.1002\/mds.21683","article-title":"Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies","volume":"22","author":"Francis","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0925","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/brain\/awp315","article-title":"Reversing cognitive-motor impairments in Parkinson's disease patients using a computational modelling approach to deep brain stimulation programming","volume":"133","author":"Frankemolle","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0930","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1126\/science.1164901","article-title":"Spinal cord stimulation restores locomotion in animal models of Parkinson's disease","volume":"323","author":"Fuentes","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0935","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/mds.21878","article-title":"Quality of life in early Parkinson's disease treated with Levodopa\/Carbidopa\/Entacapone","volume":"24","author":"Fung","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0940","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.tips.2007.06.005","article-title":"The evasive nature of drug efficacy: implications for drug discovery","volume":"28","author":"Galandrin","year":"2007","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0945","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.bbr.2003.12.016","article-title":"Alpha-2 agonist-induced memory impairment is mediated by the \u03b12A-adrenoceptor subtype","volume":"153","author":"Galeotti","year":"2004","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0950","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.neuroscience.2004.04.001","article-title":"Alpha-2 agonist induce amnesia through activation of the Gi-protein signaling pathway","volume":"126","author":"Galeotti","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0955","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2165\/00023210-200822070-00003","article-title":"Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease","volume":"22","author":"Gallagher","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0960","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/smrv.2002.0229","article-title":"Parkinson's disease and sleep","volume":"7","author":"Garcia-Borreguero","year":"2003","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0965","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0149-7634(98)00014-1","article-title":"Reaction time deficits and Parkinson's disease","volume":"22","author":"Gauntlett-Gilbert","year":"1998","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0970","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1124\/mol.66.1.97","article-title":"Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: evidence for induction of ligand-specific receptor states","volume":"66","author":"Gay","year":"2004","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0975","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/sj.bjp.0705116","article-title":"Functional coupling of the human dopamine D2 receptor with G[\u03b1]i1, G[\u03b1]i2, G[\u03b1]i3 and G[\u03b1]o G proteins: evidence for agonist regulation of G protein selectivity","volume":"138","author":"Gazi","year":"2003","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0980","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1634\/stemcells.2006-0364","article-title":"Concise review: therapeutic strategies for Parkinson's disease based on the modulation of adult neurogenesis","volume":"25","author":"Geraerts","year":"2007","journal-title":"Stem Cells"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0985","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/S1471-1931(00)00019-7","article-title":"Molecular effects of dopamine on striatal-projection pathways","volume":"23","author":"Gerfen","year":"2000","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0990","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.biopsych.2006.05.031","article-title":"Dopamine D2-like receptors and the antidepressant response","volume":"61","author":"Gershon","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb0995","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0149-7634(00)00028-2","article-title":"The role of the locus coeruleus in the development of Parkinson's disease","volume":"24","author":"Gesi","year":"2000","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1000","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.parkreldis.2006.08.006","article-title":"L-Dopa infusion does not improve explicit sequence learning in Parkinson's disease","volume":"13","author":"Ghilardi","year":"2007","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1005","doi-asserted-by":"crossref","first-page":"18754","DOI":"10.1073\/pnas.0704908104","article-title":"Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease","volume":"104","author":"Ghosh","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1010","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3758\/CABN.5.2.212","article-title":"Individual capacity differences predict working memory performance and prefrontal activity following dopamine receptor stimulation","volume":"5","author":"Gibbs","year":"2005","journal-title":"Cogn Affect Behav Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1015","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.neuroscience.2005.11.055","article-title":"A functional magnetic resonance imaging study of the effects of pergolide, a dopamine receptor agonist, on component processes of working memory","volume":"139","author":"Gibbs","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1020","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.pnpbp.2006.06.017","article-title":"Effects of the dopamine agonist piribedil on prefrontal temporal cortical network function in normal aging as assessed by verbal fluency","volume":"31","author":"Gierski","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1025","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/syn.20330","article-title":"In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist","volume":"60","author":"Glennon","year":"2006","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1030","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jneumeth.2004.04.040","article-title":"Quantification and pharmacological characterization of dialysate levels of noradrenaline in the striatum of freely-moving rats: release from adrenergic terminals and modulation by alpha2-autoreceptors","volume":"140","author":"Gobert","year":"2004","journal-title":"J Neurosci Meth"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1035","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1124\/jpet.102.046383","article-title":"Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of \u03b12A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors","volume":"305","author":"Gobert","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1040","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/mds.21226","article-title":"Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial","volume":"22","author":"Goetz","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1045","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/mds.20464","article-title":"Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease","volume":"20","author":"Goetz","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1050","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nlm.2003.07.003","article-title":"Acetylcholine modulation of neural systems involved in learning and memory","volume":"80","author":"Gold","year":"2003","journal-title":"Neurobiol Learn Mem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1055","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.179.4075.816","article-title":"Tremor and involuntary movements in monkeys: effects of L-Dopa and a dopamine receptor stimulating agent","volume":"179","author":"Goldstein","year":"1973","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1060","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1210\/me.2005-0363","article-title":"Dependence of electrical activity and calcium influx-controlled prolactin release on adenylyl cyclase signaling pathway in pituitary lactotrophs","volume":"20","author":"Gonzalez-Iglesias","year":"2006","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1065","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1210\/en.2007-0980","article-title":"Dopamine inhibits basal prolactin release in pituitary lactotrophs through pertussis toxin-sensitive and -insensitive signaling pathways","volume":"149","author":"Gonzalez-Iglesias","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1070","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.2174\/1389450110607011399","article-title":"Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders","volume":"7","author":"Gould","year":"2006","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1075","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S1364-6613(99)01310-8","article-title":"Neurogenesis in adulthood: a possible role in learning","volume":"3","author":"Gould","year":"1999","journal-title":"Trends Cogn Sci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1080","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/1531-8257(199901)14:1<10::AID-MDS1005>3.0.CO;2-4","article-title":"A data-driven approach to the study of heterogeneity in idiopathic Parkinson's disease: identification of three distinct subtypes","volume":"14","author":"Graham","year":"1999","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1085","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1212\/WNL.63.8_suppl_3.S8","article-title":"Nocturnal problems occurring in Parkinson's disease","volume":"63","author":"Grandas","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1090","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1212\/01.WNL.0000031426.21683.E2","article-title":"Cognitive impairments in advanced PD without dementia","volume":"59","author":"Green","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1095","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1586\/14789450.4.6.783","article-title":"Kinase signaling pathways as potential targets in the treatment of Parkinson's disease","volume":"4","author":"Greggio","year":"2007","journal-title":"Expert Rev Proteomics"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1100","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1124\/mol.108.048033","article-title":"Cross-talk between dopaminergic and noradrenergic systems in the rat ventral tegmental area, locus coeruleus, and dorsal hippocampus","volume":"74","author":"Guiard","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1105","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/sj.ijir.3900719","article-title":"Dopamine and sexual function","volume":"13","author":"Guiliano","year":"2001","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1110","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s00210-003-0827-z","article-title":"The alpha(2)-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats","volume":"368","author":"Haapalinna","year":"2003","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1115","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0014-2999(98)00077-6","article-title":"Facilitation of cognitive functions by a specific \u03b12-adrenoceptor antagonist, atipamezole","volume":"347","author":"Haapalinna","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1120","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1152\/physrev.00043.2007","article-title":"Histamine in the nervous system","volume":"88","author":"Haas","year":"2008","journal-title":"Physiol Rev"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1125","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.nurt.2008.10.033","article-title":"Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer's and Parkinson's diseases","volume":"6","author":"Halperin","year":"2009","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1130","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/jcp.0b013e3181602fab","article-title":"Effect of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers","volume":"28","author":"Hamidovic","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1135","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.parkreldis.2009.10.007","article-title":"Sexual and relationship dysfunction in people with Parkinson's disease","volume":"16","author":"Hand","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1140","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.gde.2009.03.008","article-title":"The genetics of Parkinson's syndromes: a critical review","volume":"19","author":"Hardy","year":"2009","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1145","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.lfs.2003.07.005","article-title":"The [35S]GTP\u03b3S binding assay: approaches and applications in pharmacology","volume":"74","author":"Harrison","year":"2003","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1150","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/mds.22432","article-title":"Neuroprotection trials in Parkinson's disease: systematic review","volume":"24","author":"Hart","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1155","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.conb.2006.09.002","article-title":"The role of acetylcholine in learning and memory","volume":"16","author":"Hasselmo","year":"2006","journal-title":"Curr Opin Neurobiol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1160","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000216839","article-title":"Safety and tolerability of Pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease","volume":"62","author":"Hauser","year":"2009","journal-title":"Eur Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1165","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.parkreldis.2009.08.007","article-title":"A timeline for Parkinson's disease","volume":"16","author":"Hawkes","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1170","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2174\/187152708786927822","article-title":"Selective antagonism at dopamine D3 receptors as a target for drug addiction pharmacotherapy: a review of preclinical evidence","volume":"7","author":"Heidbreder","year":"2008","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1175","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.brainresrev.2004.12.033","article-title":"The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence","volume":"49","author":"Heidbreder","year":"2005","journal-title":"Brain Res Rev"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1180","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1749-6632.2009.05149.x","article-title":"Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders","volume":"1187","author":"Heidbreder","year":"2010","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1185","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejphar.2006.08.063","article-title":"Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist","volume":"552","author":"Heinrich","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1190","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1471-4159.2008.05227.x","article-title":"Dopamine-induced toxicity is synergistically potentiated by simultaneous HSP-90 and Akt inhibition in oligodendrocyte progenitors","volume":"105","author":"Hemdan","year":"2008","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1200","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.neuropsychologia.2004.02.001","article-title":"Verbal fluency performance in dementia of the Alzheimer's type: a meta-analysis","volume":"42","author":"Henry","year":"2004","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1205","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1006\/exnr.1998.6996","article-title":"Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat","volume":"155","author":"Henry","year":"1999","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1210","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0014-4886(03)00064-5","article-title":"Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease","volume":"183","author":"Henry","year":"2003","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1215","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/1531-8257(199909)14:5<744::AID-MDS1006>3.0.CO;2-7","article-title":"The \u03b12-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dihydroxyphenylalanine in the MPTP-lesioned primate model of Parkinson's disease","volume":"14","author":"Henry","year":"1999","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1220","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.neuropharm.2006.11.008","article-title":"Differential agonist and inverse agonist profile of antipsychotics at D2L receptors coupled to GIRK potassium channels","volume":"52","author":"Heusler","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1225","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1212\/01.wnl.0000191154.78131.f6","article-title":"Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways","volume":"65","author":"Hilker","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1230","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1002\/mds.21106","article-title":"Antiparkinsonian effects of the novel D3\/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: mediation by D2, not D3, dopamine receptors","volume":"21","author":"Hill","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1235","doi-asserted-by":"crossref","first-page":"18091","DOI":"10.1074\/jbc.M107731200","article-title":"Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors","volume":"277","author":"Hillion","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1240","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00228-007-0427-9","article-title":"Disease progression, drug action and Parkinson's disease: why time cannot be ignored","volume":"64","author":"Holford","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1245","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0306-4522(99)00260-2","article-title":"Adrenergic \u03b12C-receptors reside in rat striatal GABAergic projection neurons: comparison of radioligand binding and immunohistochemistry","volume":"93","author":"Holmberg","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1250","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1136\/bmj.324.7352.1483","article-title":"Sleep attacks in patients taking dopamine agonists: review","volume":"324","author":"Homann","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1255","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0014-2999(82)90283-7","article-title":"Is TL99 a selective presynaptic dopamine receptor agonist?","volume":"83","author":"Horn","year":"1982","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1260","first-page":"19","article-title":"Biochemical pathophysiology in Parkinson's disease","volume":"45","author":"Hornykiewicz","year":"1986","journal-title":"Adv Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1265","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000122634","article-title":"Influence of dopaminergic agonists and antagonists on serum prolactin concentrations in the rat","volume":"22","author":"Horowski","year":"1976","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1270","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/j.1468-1331.2006.01547.x","article-title":"Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease","volume":"13","author":"Horstink","year":"2006","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1275","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/mds.20201","article-title":"Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists","volume":"19","author":"Horvath","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1280","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1124\/jpet.104.071142","article-title":"Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3, 4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys","volume":"311","author":"Hsu","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1285","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.physbeh.2004.08.018","article-title":"Dopamine and serotonin: influences on male sexual behavior","volume":"83","author":"Hull","year":"2004","journal-title":"Physiol Behav"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1290","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.parkreldis.2009.02.009","article-title":"Parkinsonism and related disorders","volume":"15","author":"Invernizzi","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1295","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.pnpbp.2004.05.026","article-title":"Role of presynaptic alpha2-adrenoceptors in antidepressant action: recent findings from microdialysis studies","volume":"28","author":"Invernizzi","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1300","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2165\/00002512-200320110-00006","article-title":"Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison","volume":"20","author":"Inzelberg","year":"2003","journal-title":"Drugs Aging"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1305","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1471-4159.2005.03625.x","article-title":"Pramipexole protects against MPTP toxicity in non-human primates","volume":"96","author":"Iravani","year":"2006","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1310","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1124\/jpet.106.110429","article-title":"In primates, the selective 5-hydroxytryptamine 1a agonist inhibits Levo-Dopa-induced dyskinesia but only with increased motor disability","volume":"319","author":"Iravani","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1315","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1600-0404.2008.01049.x","article-title":"Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal Levodopa infusion","volume":"118","author":"Isacson","year":"2008","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1320","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/syn.20603","article-title":"Regional analysis of age-related decline in dopamine transporters and dopamine D2-like receptors in human striatum","volume":"63","author":"Ishibashi","year":"2009","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1325","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1196\/annals.1417.012","article-title":"Ablation of the central noradrenergic neurons for unravelling their roles in stress and anxiety","volume":"1129","author":"Itoi","year":"2008","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1330","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/S0026-895X(25)08744-9","article-title":"Sequestration of the short and long isoforms of dopamine D2 receptors expressed in Chinese hamster ovary cells","volume":"49","author":"Itokawa","year":"1996","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1335","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0165-0327(99)00199-8","article-title":"Open pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression","volume":"61","author":"Izumi","year":"2000","journal-title":"J Affect Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1340","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00499902","article-title":"Dopaminergic modulation of hippocampal noradrenaline release: evidence for \u03b12-antagonistic effects of some dopamine receptor agonists and antagonists","volume":"330","author":"Jackisch","year":"1985","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1345","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.expneurol.2006.10.005","article-title":"Decreased expression of L-Dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets","volume":"204","author":"Jackson","year":"2007","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1350","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00702-009-0323-9","article-title":"The dopamine D2 receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with L-dopa","volume":"117","author":"Jackson","year":"2010","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1355","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.neuropsychologia.2009.12.010","article-title":"Medication impairs probalistic classification learning in Parkinson's disease","volume":"48","author":"Jahanshahi","year":"2010","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1360","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","article-title":"Parkinson's disease: clinical features and diagnosis","volume":"79","author":"Jankovic","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1365","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/mds.20974","article-title":"Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia","volume":"21","author":"Janvin","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1370","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0006-2952(97)00631-X","article-title":"Ligand efficacy and potency at recombinant \u03b12-adrenergic receptors","volume":"55","author":"Jasper","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-7091-6360-3_1","article-title":"Post mortem studies in Parkinson's disease\u2014is it possible to detect brain areas for specific symptoms?","volume":"56","author":"Jellinger","year":"1999","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1380","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1007\/BF00819559","article-title":"Parkinson's disease: pathological mechanisms and actions of piribedil","volume":"239","author":"Jenner","year":"1992","journal-title":"J Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1385","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1353-8020(02)00115-3","article-title":"The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease","volume":"9","author":"Jenner","year":"2003","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1390","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1002\/ana.21489","article-title":"Functional models of Parkinson's disease: a valuable tool in the development of novel therapies","volume":"64","author":"Jenner","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1395","doi-asserted-by":"crossref","first-page":"S585","DOI":"10.1002\/mds.22022","article-title":"Preventing and controlling dyskinesia in Parkinson's disease\u2014a view of current knowledge and future opportunities","volume":"23","author":"Jenner","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1400","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrn2471","article-title":"Molecular mechanisms of L-DOPA-induced dyskinesia","volume":"9","author":"Jenner","year":"2008","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1405","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0014-2999(75)90160-0","article-title":"The influence of piribedil (ET495) on components of locomotor activity","volume":"33","author":"Jenner","year":"1975","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1410","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1038\/sj.npp.1301603","article-title":"Stimulation of \u03b12-adrenoceptors suppresses excitatory synaptic transmission in the medial prefrontal cortex of rat","volume":"33","author":"Ji","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1415","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bbr.2004.07.006","article-title":"Impaired procedural learning in obsessive-compulsive disorder and Parkinson's disease, but not in major depressive disorder","volume":"157","author":"Joel","year":"2005","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1420","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/00002826-198610000-00005","article-title":"Neuroendocrine effects of the dopamine agonist piribedil in depressed patients","volume":"9","author":"Joffe","year":"1986","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1425","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.parkreldis.2008.03.005","article-title":"Impaired cognitive performance in Parkinson's disease in related to caudate dopaminergic hypofunction and hippocampal atrophy","volume":"15","author":"Jokinen","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1430","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.neuropharm.2005.11.010","article-title":"Expression of D2 receptor isoforms in cultured neurons reveals equipotent autoreceptor function","volume":"50","author":"Jomphe","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1435","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2174\/1389450110607011421","article-title":"Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions","volume":"7","author":"Jope","year":"2006","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1440","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1527-3458.2005.tb00046.x","article-title":"Ropinirole, a non-ergoline dopamine agonist","volume":"11","author":"Jost","year":"2005","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1445","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.coph.2006.11.004","article-title":"Dopamine D3 receptor agonists for protection and repair in Parkinson's disease","volume":"7","author":"Joyce","year":"2007","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1450","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0014-4886(03)00353-4","article-title":"Neuroprotective effects of the novel D3\/D2 receptor agonist and antiparkinson agent, S32504, in vivo against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP): a comparison to ropinirole","volume":"184","author":"Joyce","year":"2003","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1455","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0149-7634(02)00065-9","article-title":"Functional imaging studies of dopamine system and cognition in normal aging and Parkinson's disease","volume":"26","author":"Kaasinen","year":"2002","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1460","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejphar.2007.06.059","article-title":"A proteomic approach to receptor signaling: molecular mechanisms and therapeutic implications derived from discovery of the dopamine D2 receptor signalpex","volume":"572","author":"Kabbani","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3565(24)39196-7","article-title":"In vivo gene modification elucidates subtype-specific functions of \u03b12-adrenergic receptors","volume":"293","author":"Kable","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1470","first-page":"707","article-title":"Beneficial effect of pramipexole for motor function and depression in Parkinson's disease","volume":"4","author":"Kano","year":"2008","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1475","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/j.1471-4159.2007.04852.x","article-title":"\u03b12-Adrenergic receptors activate cyclic AMP-response element-binding protein through arachidonic acid metabolism and protein kinase A in a subtype-specific manner","volume":"103","author":"Karkoulias","year":"2007","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1480","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0006-3223(95)00666-4","article-title":"Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression","volume":"40","author":"Kasahara","year":"1996","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1485","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.pharmthera.2005.12.004","article-title":"5-hydroxytryptamine receptors in the human cardiovascular system","volume":"111","author":"Kaumann","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1490","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.neuropsychologia.2009.01.002","article-title":"Switching between abstract rules reflects disease severity but not dopaminergic status in Parkinson's disease","volume":"47","author":"Kehagia","year":"2009","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1495","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.2174\/156802608785161394","article-title":"D2 receptor partial agonists: treatment of CNS disorders of dopamine function","volume":"8","author":"Kehne","year":"2008","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1500","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0014-2999(75)90325-8","article-title":"The importance of extrapyramidal function for the induction and antagonism of harmine tremor","volume":"32","author":"Kelly","year":"1975","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1505","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1146\/annurev.pharmtox.42.091401.113012","article-title":"Drug efficacy at G-protein-coupled receptors","volume":"42","author":"Kenakin","year":"2002","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1510","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/jnr.10426","article-title":"Protective effect of dopamine D2 agonists in cortical neurons via the phosphatidylinositol 3 kinase cascade","volume":"70","author":"Kihara","year":"2002","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1515","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1124\/jpet.301.3.1179","article-title":"Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs","volume":"301","author":"Kilts","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1520","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1210\/me.2003-0066","article-title":"Distinct regulation of internalization and mitogen-activated protein kinase activation by two isoforms of the dopamine D2 receptor","volume":"18","author":"Kim","year":"2004","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1525","doi-asserted-by":"crossref","first-page":"37409","DOI":"10.1074\/jbc.M106728200","article-title":"Differential regulation of the dopamine D2 and D3 receptors by G protein-coupled receptor kinases and \u03b2-arrestins","volume":"276","author":"Kim","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1530","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S0028-3932(02)00317-2","article-title":"Cognitive effects of the dopamine receptor agonist pergolide","volume":"41","author":"Kimberg","year":"2003","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1535","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1097\/00001756-199711100-00032","article-title":"Effects of bromocriptine on human subjects depends on working memory capacity","volume":"8","author":"Kimberg","year":"1997","journal-title":"NeuroReport"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1540","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1212\/01.wnl.0000230572.07791.22","article-title":"Dissociating apathy and depression in Parkinson disease","volume":"67","author":"Kirsch-Darrow","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1545","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/mds.22437","article-title":"How cautious should we be when assessing apathy with the unified Parkinson's disease rating scale?","volume":"24","author":"Kirsch-Darrow","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1550","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1023\/A:1023207222944","article-title":"Neuroprotective mechanisms of antiparkinsonian dopamine D2-receptor subfamily agonists","volume":"28","author":"Kitamura","year":"2003","journal-title":"Neurochem Res"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1555","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.neuropharm.2008.03.015","article-title":"Recruitment of \u03b2-arrestin2 to the dopamine D2 receptor: insights into anti-psychotic and anti-parkinsonian drug receptor signaling","volume":"54","author":"Klewe","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1560","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.neuint.2007.06.036","article-title":"\u03b12-adrenoceptor subtypes\u2014unexpected functions for receptors and ligands derived from gene-targeted mouse models","volume":"51","author":"Knaus","year":"2007","journal-title":"Neurochem Int"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1565","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00213-008-1070-6","article-title":"Neurochemical responses to antidepressants in the prefrontal cortex of mice and their efficacy in preclinical models of anxiety-like and depression-like behavior: a comparative and correlational study","volume":"197","author":"Kobayashi","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1570","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2174\/1389450110607011377","article-title":"Glycogen synthase kinase-3\u2014an overview of an over-achieving protein kinase","volume":"7","author":"Kockeritz","year":"2006","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1575","first-page":"S89","article-title":"Reserpine-induced tremor, rigidity and hypokinesia in rats: effects of piribedil in comparison with other dopaminergic agonists","volume":"237","author":"Koek","year":"1990","journal-title":"J Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1580","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1093\/cercor\/bhp047","article-title":"Background dopamine concentration dependently facilitates long-term potentiation in rat prefrontal cortex through postsynaptic activation of extracellular signal-regulated kinases","volume":"19","author":"Kolomiets","year":"2009","journal-title":"Cereb Cortex"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1585","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1517\/13543784.14.4.377","article-title":"Novel pharmacological strategies for motor complications in Parkinson's disease","volume":"14","author":"Konitsiotis","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1590","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0149-7634(94)00019-W","article-title":"Dopamine receptor supersensitivity","volume":"19","author":"Kostrzewa","year":"1995","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1595","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa035275","article-title":"Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease","volume":"349","author":"Krack","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1600","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1627-4830(07)92028-0","article-title":"A meta-analytic approach to the efficacy in monotherapy of dopaminergic agonists in the treatment of Parkinson's disease","volume":"7","author":"Krack","year":"2007","journal-title":"Neurol Psychiatr G\u00e9riatr"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1605","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/PL00005045","article-title":"Alpha2-adrenoceptors in oppossum kidney cells couple to stimulation of mitogen-activated protein kinase independently of adenylyl cyclase inhibition","volume":"356","author":"Kribben","year":"1997","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1610","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nrn2196","article-title":"Translational principles of deep brain stimulation","volume":"8","author":"Kringelbach","year":"2007","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1615","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3758\/CABN.6.1.86","article-title":"Dopamine D2 receptors mediate reversal learning in male C57BL\/6J mice","volume":"6","author":"Kruzich","year":"2006","journal-title":"Cogn Affect Behav Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1620","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/sj.bjp.0703964","article-title":"Agonist trafficking of Gi\/o-mediated \u03b12A-adrenoceptor responses in HeL 92.1.7 cells","volume":"132","author":"Kukkonen","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1625","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/1531-8257(200007)15:4<613::AID-MDS1005>3.0.CO;2-F","article-title":"Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients","volume":"15","author":"Kulisevsky","year":"2000","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1630","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/11319860-000000000-00000","article-title":"Tolerability and safety of ropinirole versus other dopamine agonists and Levodopa in the treatment of Parkinson's disease","volume":"33","author":"Kulisevsky","year":"2010","journal-title":"Drug Saf"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1635","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.neuropharm.2009.01.019","article-title":"Evaluation of D2 and D3 dopamine receptor selective compounds on L-Dopa-dependent abnormal involuntary movements in rats","volume":"56","author":"Kumar","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1640","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s002130050190","article-title":"Effects of acute administration of D-amphetamine and haloperidol on procedural learning in man","volume":"129","author":"Kumari","year":"1997","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1645","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/j.1743-6109.2008.01083.x","article-title":"Loss of libido in Parkinson's disease","volume":"6","author":"Kummer","year":"2009","journal-title":"J Sex Med"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1650","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/WNN.0b013e3181b278f9","article-title":"Depression impairs executive functioning in Parkinson disease patients with low educational level","volume":"22","author":"Kummer","year":"2009","journal-title":"Cogn Behav Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1655","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1006\/mcne.1998.0722","article-title":"Human dopamine D3 and D2L receptors couple to inward rectifier potassium channels in mammalian cell lines","volume":"12","author":"Kuzhikandathil","year":"1998","journal-title":"Mol Cell Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1660","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2174\/156802608785161457","article-title":"Receptor-binding and pharmacokinetic properties of dopaminergic agonists","volume":"8","author":"Kvernmo","year":"2008","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1665","first-page":"A163","article-title":"Comparison of Trivastal Retard 50 (150mg\/day per os) and placebo in early combination with L-Dopa in Parkinson's disease: An international, double-blind, controlled study in patients treated for 6months","volume":"58","author":"Kwiecinski","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1670","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/sj.npp.1300114","article-title":"Selective antagonism at dopamine D3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex","volume":"28","author":"Lacroix","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1675","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/00023210-200822050-00004","article-title":"Antiparkinsonian medication and pathological gambling","volume":"22","author":"Lader","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1680","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0306-4522(02)00185-9","article-title":"Behavioral and neurochemical characterization of alpha(2A)-adrenergic receptor knockout mice","volume":"113","author":"L\u00e4hdesmaki","year":"2002","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1685","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0028-3908(03)00080-7","article-title":"\u03b12-adrenergic drug effects on brain monoamines, locomotion, and body temperature are largely abolished in mice lacking the \u03b12A-adrenoceptor subtype","volume":"44","author":"L\u00e4hdesmaki","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1690","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0014-2999(95)00410-M","article-title":"Effects of a selective \u03b12-adrenoceptor antagonist, atipamezole, on hypothalamic histamine and noradrenaline release in vivo","volume":"285","author":"Laitinen","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1695","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1124\/mol.108.050534","article-title":"A dopamine D2 receptor mutant capable of G protein-mediated signalling but deficient in arrestin binding","volume":"75","author":"Lan","year":"2009","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1700","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.expneurol.2005.06.006","article-title":"Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?","volume":"197","author":"Lane","year":"2006","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1705","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bbr.2010.04.034","article-title":"Pre-treatment with dopamine agonists influence L-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat","volume":"213","author":"Lane","year":"2010","journal-title":"Behav. Brain Res"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1710","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1124\/jpet.107.134296","article-title":"G protein coupling and ligand selectivity of the D2L and D3 dopamine receptors","volume":"325","author":"Lane","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1715","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/00003495-199039030-00009","article-title":"Pergolide: a review of its pharmacological properties and therapeutic potential in Parkinson's disease","volume":"39","author":"Langtry","year":"1990","journal-title":"Drugs"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1720","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.neuroscience.2005.09.031","article-title":"Noradrenergic modulation of cognitive function in rat medial prefrontal cortex as measured by attentional set shifting capability","volume":"137","author":"Lapiz","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1725","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00213-004-2096-z","article-title":"Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats","volume":"179","author":"Laszy","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1730","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.neuropharm.2005.04.022","article-title":"The dopamine D3 receptor and drug dependence: effects on reward or beyond?","volume":"49","author":"Le Foll","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1735","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.neuropharm.2006.05.002","article-title":"Gz proteins are functionally coupled to dopamine D2-like receptors in vivo","volume":"51","author":"Leck","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1740","doi-asserted-by":"crossref","first-page":"7931","DOI":"10.1523\/JNEUROSCI.22-18-07931.2002","article-title":"Impaired D2 dopamine receptor function in mice lacking type 5 adenylyl cyclase","volume":"22","author":"Lee","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1745","doi-asserted-by":"crossref","first-page":"35671","DOI":"10.1074\/jbc.M401923200","article-title":"Dopamine D1 and D2 receptor coactivation generates a novel phospholipase C-mediated calcium signal","volume":"279","author":"Lee","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1750","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0306-4522(97)00578-2","article-title":"Localization of \u03b12C-adrenergic receptor immunoreactivity in catecholaminergic neurons in the rat central nervous system","volume":"84","author":"Lee","year":"1998","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1755","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.clinthera.2009.01.012","article-title":"The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies","volume":"31","author":"Leentjens","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1760","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1034\/j.1600-0447.2002.02045.x","article-title":"Markers for depression in Parkinson's disease","volume":"106","author":"Leentjens","year":"2002","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1765","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/mds.10387","article-title":"Higher incidence of depression preceding the onset of Parkinson's disease: a register study","volume":"18","author":"Leentjens","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1770","article-title":"2-year results of the Regain Study, a placebo-controlled trial with the non-ergot dopamine agonist piribedil as early treatment of Parkinson's disease (PD)","author":"Lees","year":"2005","journal-title":"Eur Fed Neurol Sci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1775","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1126\/science.1109237","article-title":"Transduction of receptor signals by \u03b2-arrestins","volume":"308","author":"Lefkowitz","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1780","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1468-1331.2008.02213.x","article-title":"Dopamine agonists in the treatment of non-motor symptoms of Parkinson's disease: depression","volume":"15","author":"Lemke","year":"2008","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1785","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1176\/jnp.17.2.214","article-title":"Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole","volume":"17","author":"Lemke","year":"2005","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1790","doi-asserted-by":"crossref","first-page":"R48","DOI":"10.1093\/hmg\/ddp012","article-title":"Parkinson's disease: from monogenic forms to genetic susceptibility factors","volume":"18","author":"Lesage","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1795","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/00048670802607238","article-title":"Dopamine vs noradrenaline: inverted-U effects and ADHD theories","volume":"43","author":"Levy","year":"2009","journal-title":"Aust NZ J Psychiatry"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1800","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/cercor\/bhj043","article-title":"Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits","volume":"16","author":"Levy","year":"2006","journal-title":"Cereb Cortex"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1805","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s10495-008-0309-3","article-title":"Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps","volume":"14","author":"Levy","year":"2009","journal-title":"Apoptosis"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1810","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/jnnp.2003.033530","article-title":"Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach","volume":"76","author":"Lewis","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1815","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.nurt.2008.01.007","article-title":"Protection against Parkinson's disease progression: clinical experience","volume":"5","author":"LeWitt","year":"2008","journal-title":"Neurother J Am Soc Exp Neurother"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1820","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.brainres.2007.01.130","article-title":"NF-kappaB contributes to 6-hydroxydopamine-induced apoptosis of nigral dopaminergic neurons through p53","volume":"1145","author":"Liang","year":"2007","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1825","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.neuroimage.2005.10.031","article-title":"Using fMRI to decompose the neural processes underlying the Wisconsin Card Sorting Test","volume":"30","author":"Lie","year":"2006","journal-title":"Neuroimage"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1830","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.tips.2009.03.001","article-title":"Prospects of stem cell therapy for replacing dopamine neurons in Parkinson's disease","volume":"30","author":"Lindvall","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1835","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0022-3565(24)38124-8","article-title":"Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures","volume":"289","author":"Ling","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1840","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00228-009-0658-z","article-title":"Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients","volume":"65","author":"Liu","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1845","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.euroneuro.2008.07.012","article-title":"Blockade of dopamine D3 receptors in frontal cortex, but not in subcortical structures, enhances social recognition in rats: similar actions of D1 receptor agonists, but not of D2 antagonists","volume":"19","author":"Loiseau","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1850","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/WCO.0b013e3281e66942","article-title":"Update on pathogenesis and treatment of essential tremor","volume":"20","author":"Lorenz","year":"2007","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1855","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/cercor\/8.3.218","article-title":"Opposing roles for dopamine and serotonin in the modulation of human spatial working memory functions","volume":"8","author":"Luciana","year":"1998","journal-title":"Cereb Cortex"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1860","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1865","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2967\/jnumed.109.066811","article-title":"Dopamine cell implantation in Parkinson's disease: long-term and 18F-Fdopa PET outcomes","volume":"51","author":"Ma","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1870","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.neuropsychologia.2009.02.018","article-title":"Distractibility with advancing age and Parkinson's disease","volume":"47","author":"Machado","year":"2009","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1875","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10899-006-9041-5","article-title":"Toward an animal model of gambling: delay discounting and the allure of unpredictable outcomes","volume":"23","author":"Madden","year":"2007","journal-title":"J Gambl Stud"},{"issue":"Suppl 4","key":"10.1016\/j.pharmthera.2010.06.002_bb1880","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1353-8020(09)70826-0","article-title":"Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance","volume":"15","author":"Maggio","year":"2009","journal-title":"Park Relat Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1885","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1046\/j.1471-4159.2003.02038.x","article-title":"Potent activation of dopamine D3\/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole","volume":"87","author":"Maggio","year":"2003","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1890","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1073\/pnas.90.7.3103","article-title":"Coexpression studies with mutant muscarinic\/adrenergic receptors provide evidence for intermolecular \u201ccross talk\u201d between G-protein-linked receptors","volume":"90","author":"Maggio","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1895","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.tips.2007.06.002","article-title":"GPCR functional selectivity has therapeutic impact","volume":"28","author":"Mailman","year":"2007","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1900","doi-asserted-by":"crossref","first-page":"488","DOI":"10.2174\/138161210790361461","article-title":"Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?","volume":"16","author":"Mailman","year":"2010","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1905","doi-asserted-by":"crossref","first-page":"14363","DOI":"10.1523\/JNEUROSCI.3928-08.2008","article-title":"RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation\/activation","volume":"28","author":"Malagelada","year":"2008","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1910","doi-asserted-by":"crossref","first-page":"9104","DOI":"10.1523\/JNEUROSCI.20-24-09104.2000","article-title":"Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus","volume":"20","author":"Malberg","year":"2000","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1915","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1093\/brain\/awp166","article-title":"Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's disease","volume":"132","author":"Manganelli","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1920","unstructured":"Mannoury la Cour, C., Salles, M.J., Pasteau, V., & Millan, M.J. (2009). Intracellular cascades underlying phosphorylation of Akt and GSK-3\u03b2 by activation of human D2L and D3 receptors stably expressed in CHO cells. SFN Abstr. 630.30."},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1925","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1006\/exnr.2002.8055","article-title":"Both short- and long-acting D1\/D2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus)","volume":"179","author":"Maratos","year":"2003","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1930","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/mds.1149","article-title":"Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug na\u00efve MPTP-lesioned common marmosets (Callithrix jacchus)","volume":"16","author":"Maratos","year":"2001","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1935","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.neuropharm.2007.12.011","article-title":"Antagonistic cannabinoid CB1\/dopamine D2 receptor interactions in striatal CB1\/D2 heteromers. A combined neurochemical and behavioural analysis","volume":"54","author":"Marcellino","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1940","doi-asserted-by":"crossref","first-page":"26016","DOI":"10.1074\/jbc.M710349200","article-title":"Identification of dopamine D1\u2013D3 receptor heteromers: indications for a role of synergistic D1\u2013D3 receptor interactions in the striatum","volume":"38","author":"Marcellino","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1945","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.brainresrev.2004.02.002","article-title":"Noradrenergic mechanisms in neurodegenerative diseases: a theory","volume":"45","author":"Marien","year":"2004","journal-title":"Brain Res Rev"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1950","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/0269881107083836","article-title":"Comparative effects of the dopaminergic agonists piribedil and bromocriptine in three different memory paradigms in rodents","volume":"22","author":"Marighetto","year":"2008","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1955","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00702-008-0060-5","article-title":"Effect of locus coeruleus denervation on Levodopa-induced motor fluctuations in hemiparkinsonian rats","volume":"115","author":"Marin","year":"2008","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1960","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2165\/00023210-199707040-00005","article-title":"Pergolide: a review of its pharmacology and therapeutic use in Parkinson's disease","volume":"7","author":"Markham","year":"1997","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1965","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1212\/01.wnl.0000312515.52545.51","article-title":"Invited article: changing concepts in Parkinson disease: moving beyond the decade of the brain","volume":"70","author":"Marras","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1970","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/mds.22307","article-title":"Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study","volume":"24","author":"Marsh","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1975","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1006\/exnr.1998.6942","article-title":"Neuroprotective effects of the \u03b12-adrenoceptor antagonists (+)-efaroxan and (\u00b1)-idazoxan against quinolinic acid-induced lesions of the rat striatum","volume":"154","author":"Martel","year":"1998","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1980","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0014-2999(83)90298-4","article-title":"Different actions of TL-99 and 3-PPP in producing contraversive turning in the 6-OHDA-lesioned rat","volume":"92","author":"Martin","year":"1983","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1985","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/mds.21407","article-title":"Effect of medical and surgical interventions on health-related quality of life in Parkinson's disease","volume":"22","author":"Martinez-Martin","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1990","doi-asserted-by":"crossref","first-page":"13656","DOI":"10.1073\/pnas.0803522105","article-title":"Antagonism of dopamine D2 receptor\/\u03b2-arrestin 2 interaction is a common property of clinically effective antipsychotics","volume":"105","author":"Masri","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb1995","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/mds.22457","article-title":"Orthostatic hypotension, balance and falls in Parkinson's disease","volume":"24","author":"Matinolli","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2000","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/0006-8993(91)90624-5","article-title":"Differential modulation of (+)-amphetamine-induced rotation in unilateral substantia nigra-lesioned rats by \u03b11 as compared to \u03b12 agonists and antagonists","volume":"562","author":"Mavridis","year":"1991","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2005","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0306-4522(91)90345-O","article-title":"Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in monkeys. A possible role for the locus coeruleus in the progression of Parkinson's disease","volume":"41","author":"Mavridis","year":"1991","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2010","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s002130100736","article-title":"The \u03b12-adrenoceptor antagonists RX 821002 and yohimbine delay-dependently impair choice accuracy in a delayed non-matching-to-position task in rats","volume":"155","author":"McAllister","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2015","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0006-3223(03)00530-4","article-title":"Prevalence, etiology, and treatment of depression in Parkinson's disease","volume":"54","author":"McDonald","year":"2003","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2020","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neuroscience.2008.01.064","article-title":"Noradrenergic, but not cholinergic, deafferentation of prefrontal cortex impairs attentional set-shifting","volume":"153","author":"McGaughy","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2025","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/syn.20315","article-title":"Dose-response analysis of locomotor activity and stereotypy in dopamine D3 receptor mutant mice following acute amphetamine","volume":"60","author":"McNamara","year":"2006","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2030","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0014-2999(84)90525-9","article-title":"In vitro selectivity of lisuride and other ergot derivatives for \u03b11- and \u03b12-adrenoceptors","volume":"97","author":"McPherson","year":"1984","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2035","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1017\/S1092852900017260","article-title":"Sleep disorders associated with Parkinson's disease: role of dopamine, epidemiology, and clinical scales of assessment","volume":"13","author":"Mehta","year":"2008","journal-title":"CNS Spectr"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2040","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s002130100851","article-title":"Improved short-term spatial memory but impaired reversal learning following the dopamine D2 agonist bromocriptine in human volunteers","volume":"159","author":"Mehta","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2045","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.neuropharm.2009.08.017","article-title":"The selective D3 receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemilesioned rats","volume":"58","author":"Mela","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2050","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0026-895X(25)10474-4","article-title":"Relationship between receptor occupancy and response at striatal dopamine autoreceptors","volume":"31","author":"Meller","year":"1987","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2055","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0014-2999(89)90142-8","article-title":"The \u03b12-adrenoceptor antagonists idazoxan and yohimbine can unmask the postsynaptic dopamine agonist effects of B-HT 920","volume":"170","author":"Meltzer","year":"1989","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2060","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00002826-198902000-00003","article-title":"Piribedil therapy in Parkinson's disease. Use of the drug in the retard form","volume":"12","author":"Mentenopoulos","year":"1989","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2065","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1080\/09540260802095123","article-title":"Cognitive and behavioural impairment in Parkinson's disease","volume":"20","author":"Merims","year":"2008","journal-title":"Int Rev Psychiatry"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2070","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.parkreldis.2007.09.007","article-title":"Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease","volume":"14","author":"Merims","year":"2008","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2075","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1460-9568.2005.04238.x","article-title":"The unilateral 6-OHDA rat model of Parkinson's disease revisited: an electromyographic and behavioural analysis","volume":"22","author":"Metz","year":"2005","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2080","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2125.2008.03310.x","article-title":"Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects","volume":"67","author":"Micallef","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2085","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0922-4106(95)90013-6","article-title":"Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors","volume":"290","author":"Mierau","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2090","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00213-006-0680-0","article-title":"Postsynaptic 5-HT1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson's disease","volume":"192","author":"Mignon","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2095","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0301-0082(03)00087-X","article-title":"The neurobiology and control of anxious states","volume":"70","author":"Millan","year":"2003","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2100","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pharmthera.2005.11.006","article-title":"Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application","volume":"110","author":"Millan","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2105","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0022-3565(25)22564-2","article-title":"Multiple alpha-2 adrenergic receptor subtypes. II. Evidence for a role of rat R alpha2A adrenergic receptors in the control of nociception, motor behaviour and hippocampal synthesis of noradrenaline","volume":"270","author":"Millan","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2110","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2515\/therapie:2008041","article-title":"Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D3>D2 antagonist, S33138","volume":"63","author":"Millan","year":"2008","journal-title":"Therapie"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2115","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1124\/jpet.103.062463","article-title":"S32504, a novel naphtoxazine agonist at dopamine D3\/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole","volume":"309","author":"Millan","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2120","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1124\/jpet.103.062398","article-title":"S32504, a novel naphtoxazine agonist at dopamine D3\/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole","volume":"309","author":"Millan","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2125","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S0022-3565(24)29611-7","article-title":"Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization","volume":"297","author":"Millan","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2130","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/j.1471-4159.2006.04262.x","article-title":"Selective blockade of dopamine D3 versus D2 receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis","volume":"100","author":"Millan","year":"2007","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2135","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1124\/jpet.103.062414","article-title":"S32504, a novel naphtoxazine agonist at dopamine D3\/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole","volume":"309","author":"Millan","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2140","unstructured":"Millan, M.J., Dipace, C., Javitch, J.A., Silvano, E., Maggio, R., Gobert, A., et al. (2009). Signal-specific partial agonist properties of the antiparkinson agent, piribedil, at hD2S, hD2L and hD3 receptors: a comparison to ropinirole, pergolide and pramipexole. SFN Abstract 238.23."},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2145","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1046\/j.1460-9568.2000.00982.x","article-title":"Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of \u03b12-adrenergic and serotonin2C receptors: a comparison with citalopram","volume":"12","author":"Millan","year":"2000","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2150","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1124\/jpet.104.069625","article-title":"The serotonin1A receptor partial agonist S15535 [4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine] enhances cholinergic transmission and cognitive function in rodents: a combined neurochemical and behavioral analysis","volume":"311","author":"Millan","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2155","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/026988110001400202","article-title":"Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents","volume":"14","author":"Millan","year":"2000","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2160","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0022-3565(24)39023-8","article-title":"S18616, a highly potent, spiroimidazoline agonist at \u03b12-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine","volume":"295","author":"Millan","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2165","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1124\/jpet.102.039867","article-title":"Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes","volume":"303","author":"Millan","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2170","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.tips.2008.06.007","article-title":"Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions","volume":"29","author":"Millan","year":"2008","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2175","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/(SICI)1098-2396(200002)35:2<79::AID-SYN1>3.0.CO;2-X","article-title":"Agonist and antagonist actions of yohimbine as compared to fluparoxan at \u03b12-adrenergic receptors (AR)s, serotonin (5-HT)1A, 5-HT1B, 5-HT1D and dopamine D2 and D3 receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states","volume":"35","author":"Millan","year":"2000","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2185","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/35036228","article-title":"The prefrontal cortex and cognitive control","volume":"1","author":"Miller","year":"2000","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2190","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00213-006-0594-x","article-title":"Selective depletion of cortical noradrenaline by anti-dopamine beta-hydroxylase-saporin impairs attentional function and enhances the effects of guanfacine in the rat","volume":"190","author":"Milstein","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2195","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1212\/01.wnl.0000215428.46057.3d","article-title":"Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology","volume":"66","author":"Miyasaki","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2200","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1136\/jnnp.2006.098079","article-title":"Effect of Levodopa on cognitive function in Parkinson's disease with and without dementia, and dementia with Lewy bodies","volume":"77","author":"Molloy","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2205","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/brain\/awl326","article-title":"Cortical activity in Parkinson's disease during executive processing depends on striatal involvement","volume":"130","author":"Monchi","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2210","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.brainres.2004.07.020","article-title":"\u03b12-Adrenoceptor modulation of long-term potentiation elicited in vivo in rat occipital cortex","volume":"1021","author":"Mondaca","year":"2004","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2215","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/1531-8257(199909)14:5<725::AID-MDS1003>3.0.CO;2-L","article-title":"Treatment of Parkinson's disease should begin with a dopamine agonist","volume":"14","author":"Montastruc","year":"1999","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2220","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/1531-8257(199903)14:2<336::AID-MDS1021>3.0.CO;2-9","article-title":"A randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease","volume":"14","author":"Montastruc","year":"1999","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2225","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.1523\/JNEUROSCI.0728-09.2009","article-title":"Dose-dependent inverted U-shaped effect of dopamine (D2-like) receptor activation on focal and nonfocal plasticity in humans","volume":"29","author":"Monte-Silva","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2230","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.nbd.2007.09.004","article-title":"Extrastriatal monoamine neuron function in Parkinson's disease: an 18F-dopa PET Study","volume":"29","author":"Moore","year":"2008","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2235","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1046\/j.1471-4159.1999.0720682.x","article-title":"Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists","volume":"72","author":"Morisette","year":"1999","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2240","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.parkreldis.2009.10.003","article-title":"Identification and management of deep brain stimulation: intra- and postoperative urgencies and emergencies","volume":"16","author":"Morishita","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2245","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00702-004-0145-8","article-title":"Effects of Levodopa on cognitive functioning in moderate-to-severe Parkinson's disease (MSPD)","volume":"111","author":"Morrison","year":"2004","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2250","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1016\/j.neuropsychologia.2008.07.011","article-title":"A dopaminergic basis for working memory, learning and attentional shifting in Parkinsonism","volume":"46","author":"Moustafa","year":"2008","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2255","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00213-005-0078-4","article-title":"Lack of effects of guanfacine on executive and memory functions in healthy male volunteers","volume":"182","author":"M\u00fcller","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2260","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1523\/JNEUROSCI.18-07-02720.1998","article-title":"D1- versus D2-receptor modulation of visuospatial working memory in humans","volume":"18","author":"M\u00fcller","year":"1998","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2265","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1212\/01.wnl.0000180516.69442.95","article-title":"Cognitive profile of patients with newly diagnosed Parkinson's disease","volume":"65","author":"Muslimovic","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2270","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1093\/brain\/awm211","article-title":"Motor procedural learning in Parkinson's disease","volume":"130","author":"Muslimovic","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2275","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.neulet.2008.10.104","article-title":"Glycogen synthase kinase-3beta is associated with Parkinson's disease","volume":"449","author":"Nagao","year":"2009","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2280","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1176\/appi.ajp.158.9.1517","article-title":"Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment","volume":"158","author":"Nagaraja","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2285","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/978-3-211-73574-9_14","article-title":"Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects","volume":"72","author":"Nagatsu","year":"2007","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2290","doi-asserted-by":"crossref","first-page":"15469","DOI":"10.1074\/jbc.M707238200","article-title":"Differential modulation of Akt\/glycogen synthase kinase-3\u03b2 pathway regulates apoptotic and cytoprotective signaling responses","volume":"283","author":"Nair","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2295","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1042\/bj20030017","article-title":"Activation of phosphoinositide 3-kinase by D2 receptors prevents apoptosis in dopaminergic cell lines","volume":"373","author":"Nair","year":"2003","journal-title":"Biochem J"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2300","doi-asserted-by":"crossref","first-page":"47053","DOI":"10.1074\/jbc.M303364200","article-title":"Agonist-specific transactivation of phosphoinositide 3-kinase signaling pathway mediated by the dopamine D2 receptor","volume":"278","author":"Nair","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2305","doi-asserted-by":"crossref","first-page":"15038","DOI":"10.1074\/jbc.M900388200","article-title":"G protein-coupled receptor kinase-mediated phosphorylation regulates post-endocytic trafficking of the D2 dopamine receptor","volume":"284","author":"Namkung","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2310","doi-asserted-by":"crossref","first-page":"34103","DOI":"10.1074\/jbc.M109.055707","article-title":"G protein-coupled receptor kinase-2 constitutively regulates D2 dopamine receptor expression and signaling independently of receptor phosphorylation","volume":"284","author":"Namkung","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2315","doi-asserted-by":"crossref","first-page":"49533","DOI":"10.1074\/jbc.M408319200","article-title":"Protein kinase C mediates phosphorylation, desensitization, and trafficking of the D2 dopamine receptor","volume":"279","author":"Namkung","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2320","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1586\/ern.09.68","article-title":"Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease","volume":"9","author":"Naoi","year":"2009","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2325","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/00000542-200302000-00024","article-title":"The \u03b12-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects","volume":"98","author":"Nelson","year":"2003","journal-title":"Anesthesiology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2330","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.biopsych.2005.09.018","article-title":"The mesolimbic dopamine reward circuit in depression","volume":"59","author":"Nestler","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2335","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1038\/sj.npp.1301010","article-title":"Effects of a \u03b12C-adrenoceptor gene polymorphism on neural responses to facial expressions in depression","volume":"31","author":"Neumeister","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2340","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1081\/RRS-200029981","article-title":"Dopamine receptor signaling","volume":"24","author":"Neve","year":"2004","journal-title":"J Recept Signal Transduct"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2345","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/PL00005374","article-title":"Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors","volume":"359","author":"Newman-Tancredi","year":"1999","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2350","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1124\/jpet.102.039875","article-title":"Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D2-like receptor and alpha1\/alpha2-adrenoceptor","volume":"303","author":"Newman-Tancredi","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2355","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S0026-895X(24)12183-9","article-title":"G protein activation by human dopamine D3 receptors in high-expressing Chinese hamster ovary cells: a guanosine-5\u2032-O-(3-[35S]thio)-triphosphate binding and antibody study","volume":"55","author":"Newman-Tancredi","year":"1999","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2360","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0006-8993(01)02927-4","article-title":"Dopamine D2 receptor-mediated G-protein activation in rat striatum: functional autoradiography and influence of unilateral 6-hydroxydopamine lesions of the substantia nigra","volume":"920","author":"Newman-Tancredi","year":"2001","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2365","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/jpet.102.039883","article-title":"Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT1 and 5-HT2 receptor subtypes","volume":"303","author":"Newman-Tancredi","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2370","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0165-6147(96)10022-5","article-title":"The distribution and significance of CNS adrenoceptors examined with in situ hybridization","volume":"17","author":"Nicholas","year":"1996","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2375","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.neuropharm.2004.06.010","article-title":"The influence of G protein subtype on agonist actions at D2 dopamine receptors","volume":"47","author":"Nickolls","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2380","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejphar.2006.07.015","article-title":"A combined marble burying-locomotor activity test in mice: a practical screening test with sensitivity to different classes of anxiolytics and antidepressants","volume":"547","author":"Nicolas","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2385","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0301-0082(02)00011-4","article-title":"Dopamine and the regulation of cognition and attention","volume":"67","author":"Nieoullon","year":"2002","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2390","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/j.1471-4159.2007.04660.x","article-title":"Partial agonist actions of aripiprazole and the candidate antipychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D2L receptors are modified by co-transfection of D3 receptors: potential role of heterodimer formation","volume":"102","author":"Novi","year":"2007","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2395","first-page":"35","article-title":"\u03b12-Adrenoceptors and depression","volume":"10","author":"Nutt","year":"1996","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2400","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00003088-200645020-00001","article-title":"Pharmacokinetic optimisation in the treatment of Parkinson's disease","volume":"45","author":"Nyholm","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2405","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.bandc.2009.03.005","article-title":"The Winsconsin card sorting test and the cognitive assessment of prefrontal executive functions: a critical update","volume":"71","author":"Nyhus","year":"2009","journal-title":"Brain Cogn"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2410","doi-asserted-by":"crossref","first-page":"S548","DOI":"10.1002\/mds.22062","article-title":"Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease","volume":"23","author":"Obeso","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2415","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejphar.2008.09.015","article-title":"Bromocriptine, a dopamine D2 receptor agonist with the structure of the amino acid ergot alkaloids, induces neurite outgrowth in PC12 cells","volume":"598","author":"Oda","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2420","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.pnpbp.2006.05.007","article-title":"Dopamine D2 receptor-mediated G protein activation assessed by agonist-stimulated [35S]guanosine 5\u2032-O-(\u03b3-thiotriphosphate) binding in rat striatal membranes","volume":"30","author":"Odagaki","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2425","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00702-008-0160-2","article-title":"High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease","volume":"116","author":"Oeda","year":"2009","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2430","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/0024-3205(86)90257-2","article-title":"A comparative study of the locomotor activity effects of apomorphine and the \u201catypical dopamine agonists\u201d (Piribedil and S3608)","volume":"38","author":"Offermeier","year":"1986","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2435","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000077451","article-title":"Cabergoline stimulates synthesis and secretion of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor by mouse astrocytes in primary culture","volume":"71","author":"Ohta","year":"2004","journal-title":"Pharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2440","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/ana.21596","article-title":"Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus internal deep brain stimulation: the COMPARE trial","volume":"65","author":"Okun","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2445","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/mds.20243","article-title":"Levo-Dopa in the treatment of Parkinson's disease: current controversies","volume":"19","author":"Olanow","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2450","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","article-title":"Adagio Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson's disease","volume":"361","author":"Olanow","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2455","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1212\/WNL.0b013e3181a1d44c","article-title":"The scientific and clinical basis for the treatment of Parkinson disease","volume":"72","author":"Olanow","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2460","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.mcn.2004.10.006","article-title":"Activation of p38 N-acetylcysteine-sensitive c-Jun NH2-terminal kinase signaling cascades is required for induction of apoptosis in Parkinson's disease cybrids","volume":"28","author":"Onyango","year":"2005","journal-title":"Mol Cell Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2465","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1177\/1073858404266776","article-title":"Cognitive dysfunction in Parkinson's disease: the role of frontostriatal circuitry","volume":"10","author":"Owen","year":"2004","journal-title":"Neuroscientist"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2470","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/mds.870080408","article-title":"Terguride in fluctuating parkinsonian patients: a double-blind study versus placebo","volume":"8","author":"Pacchetti","year":"1993","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2475","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/mds.22007","article-title":"Parkinson's disease-cognitive rating scale: a new cognitive scale specific for Parkinson's disease","volume":"23","author":"Pagonabarraga","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2480","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jns.2007.03.013","article-title":"Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose","volume":"258","author":"Pahwa","year":"2007","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2485","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1212\/01.wnl.0000258660.74391.c1","article-title":"Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease","volume":"68","author":"Pahwa","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2490","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.neulet.2004.11.080","article-title":"Biological effects of pramipexole on dopaminergic neuron-associated genes: relevance to neuroprotection","volume":"377","author":"Pan","year":"2005","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2495","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.euroneuro.2005.12.002","article-title":"Dopaminergic-based pharmacotherapies for depression","volume":"16","author":"Papakostas","year":"2006","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2500","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1001\/jama.284.15.1931","article-title":"Pramipexole vs Levo-Dopa as initial treatment for Parkinson disease: a randomized controlled trial","volume":"284","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2505","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.287.13.1653","article-title":"Dopamine transporter brain imaging to assess the effects of pramipexole vs Levodopa on Parkinson disease progression","volume":"287","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2510","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/archneur.60.12.1721","article-title":"A controlled trial of rotigotine monotherapy in early Parkinson's disease","volume":"60","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2515","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1001\/archneur.61.7.1044","article-title":"Pramipexole vs Levo-Dopa as initial treatment for Parkinson disease","volume":"61","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2520","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1001\/archneurol.2009.32","article-title":"Long-term effect of initiating pramipexole vs Levodopa in early Parkinson disease","volume":"66","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2525","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1017\/S1355617708081010","article-title":"LEVO-DOPA and executive performance in Parkinson's disease: a randomized study","volume":"14","author":"Pascual-Sedano","year":"2008","journal-title":"J Int Neuropsychol Soc"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2530","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.tips.2004.10.003","article-title":"The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders","volume":"25","author":"Passani","year":"2004","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2535","first-page":"455P","article-title":"Effect of piribedil on EEG, psychomotor and cognitive function in healthy young subjects","volume":"41","author":"Patat","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2540","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1124\/jpet.102.048215","article-title":"Dissimilar pharmacological responses by a new series of imidazoline derivatives at precoupled and ligand-activated \u03b12A-adrenoceptor states: evidence for effector pathway-dependent differential antagonism","volume":"305","author":"Pauwels","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2545","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1212\/01.wnl.0000242888.30755.5d","article-title":"Clinical correlates of Levodopa-induced dopamine release in Parkinson disease: a PET study","volume":"67","author":"Pavese","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2550","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.biopsych.2005.05.044","article-title":"ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice","volume":"59","author":"Pavon","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2555","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/mds.870130207","article-title":"De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-Dopa in the MPTP-treated marmoset","volume":"13","author":"Pearce","year":"1998","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2560","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.parkreldis.2008.07.006","article-title":"Prevalence and clinical correlates of apathy in Parkinson's disease: a community-based study","volume":"15","author":"Pedersen","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2565","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.neuropharm.2008.12.007","article-title":"The preferential dopamine D3 receptor antagonist S33138 inhibits cocaine reward and cocaine-triggered relapse to drug-seeking behavior in rats","volume":"56","author":"Peng","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2570","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0006-8993(03)02766-5","article-title":"\u03b1-Adrenergic stimulation of ERK phosphorylation in astrocytes is \u03b12-specific and may be mediated by transactivation","volume":"978","author":"Peng","year":"2003","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2575","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0014-2999(98)00896-6","article-title":"Functional potencies of new antiparkinson drugs at recombinant human dopamine D1, D2 and D3 receptors","volume":"366","author":"Perachon","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2580","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/arclin\/17.5.445","article-title":"Cognitive skill learning and aging: a component process analysis","volume":"17","author":"Peretti","year":"2002","journal-title":"Arch Clin Neuropsychol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2585","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00213-004-1869-8","article-title":"Cognitive skill learning in healthy older adults after 2months of double-blind treatment with piribedil","volume":"176","author":"Peretti","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2590","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejphar.2007.08.024","article-title":"Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration","volume":"576","author":"P\u00e9rez","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2595","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s00702-009-0242-9","article-title":"Noradrenergic modulation of the motor response induced by long-term LEVO-DOPA administration in Parkinsonian rats","volume":"116","author":"P\u00e9rez","year":"2009","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2600","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.neuropsychologia.2009.12.003","article-title":"Recognition of emotional prosody is altered after subthalamic nucleus deep brain stimulation in Parkinson's disease","volume":"48","author":"P\u00e9ron","year":"2010","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2605","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.neuropsychologia.2008.09.008","article-title":"Are dopaminergic pathways involved in theory of mind? A study in Parkinson's disease","volume":"47","author":"P\u00e9ron","year":"2009","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2610","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1527-3458.2005.tb00047.x","article-title":"Pharmacological properties, central nervous system effects, and potential therapeutic applications of atipamezole, a selective \u03b12-adrenoceptor antagonist","volume":"11","author":"Pertovaara","year":"2005","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2615","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1212\/WNL.45.3_Suppl_3.S22","article-title":"A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to Levo-Dopa for the treatment of Parkinson's disease","volume":"45","author":"Pezzoli","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2620","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.clinthera.2008.05.007","article-title":"Rotigotine transdermal system for the treatment of Parkinson's disease","volume":"30","author":"Pham","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2625","first-page":"118","article-title":"A comparison of drug-induced rotation in rats lesioned in the medial forebrain bundle with 5, 6-dihydroxytryptamine or 6-hydroxytryptamine","volume":"217","author":"Pieri","year":"1975","journal-title":"Arch Int Pharmacodyn Th\u00e9r"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2630","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/22560","article-title":"Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist","volume":"400","author":"Pilla","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2635","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00213-007-0957-y","article-title":"Single dose of a dopamine agonist impairs reinforcement learning in humans: behavioral evidence from a laboratory-base measure of reward responsiveness","volume":"196","author":"Pizzagalli","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2640","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1474-4422(07)70108-4","article-title":"Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial","volume":"6","author":"Poewe","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2645","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1468-1331.2004.00820.x","article-title":"Pergolide mesylate can improve sexual dysfunction in patients with Parkinson's disease: the results of an open, prospective, 6-month follow-up","volume":"11","author":"Pohanka","year":"2004","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2650","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1468-1331.2007.01998.x","article-title":"The frequency and nature of sleep disorders in a community-based population of patients with Parkinson's disease","volume":"15","author":"Porter","year":"2008","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2655","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/archpsyc.1978.01770290091008","article-title":"Effects of a dopamine agonist piribedil in depressed patients: relationship of pretreatment homovanillic acid to antidepressant response","volume":"35","author":"Post","year":"1978","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2660","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1038\/sj.npp.1301667","article-title":"Quantitative trait locus analysis identifies rat genomic regions related to amphetamine-induced locomotion and G\u03b1i3 levels in nucleus accumbens","volume":"33","author":"Potenza","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2665","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.expneurol.2004.06.021","article-title":"Involvement of dopamine D2\/D3 receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells","volume":"190","author":"Presgraves","year":"2004","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2670","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.bandc.2008.07.013","article-title":"The impact of Parkinson's disease on sequence learning: perceptual pattern learning and executive function","volume":"69","author":"Price","year":"2009","journal-title":"Brain Cogn"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2675","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.neuroscience.2009.08.030","article-title":"Dopamine D2-class receptor supersensitivity as reflected in Ca2+ current modulation in neostriatal neurons","volume":"164","author":"Prieto","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2680","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0306-4522(95)00066-R","article-title":"Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine","volume":"67","author":"Przedborski","year":"1995","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2685","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.bbr.2006.08.035","article-title":"The depressive-like behaviors are correlated with decreased phosphorylation of mitogen-activated protein kinases in rat brain following chronic forced swim stress","volume":"175","author":"Qi","year":"2006","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2690","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bbr.2008.11.051","article-title":"A role of the extracellular signal-regulated kinase signal pathway in depressive-like behavior","volume":"199","author":"Qi","year":"2009","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2695","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.bbrc.2008.10.044","article-title":"Roles of G protein and \u03b2-arrestin in dopamine D2 receptor-mediated ERK activation","volume":"377","author":"Quan","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2700","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/mds.21667","article-title":"Quality of life in Parkinson's disease: the relative importance of the symptoms","volume":"23","author":"Rahman","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2705","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0014-2999(03)02087-9","article-title":"Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms","volume":"475","author":"Ramirez","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2710","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/(SICI)1096-9861(19990125)403:4<459::AID-CNE3>3.0.CO;2-9","article-title":"Morphometric studies of the aged hippocampus: I. Volumetric analysis in behaviorally characterized rats","volume":"403","author":"Rapp","year":"1999","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2715","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/mds.1143","article-title":"Idazoxan, an alpha-2 antagonist, and L-Dopa-induced dyskinesia in patients with Parkinson's disease","volume":"16","author":"Rascol","year":"2001","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2720","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/mds.22922","article-title":"Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over study","volume":"25","author":"Rascol","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2725","first-page":"S200","article-title":"Orodispersible piribedil, (S90049) to abort off episodes in apomorphine-responder patients with advanced Parkinson's disease: a single dose randomized, double-blind, placebo-controlled cross-over study","volume":"23","author":"Rascol","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2730","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1002\/mds.20988","article-title":"Development of dyskinesias in a 5-year trial of ropinirole and L-DOPA","volume":"21","author":"Rascol","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2735","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/mds.21122","article-title":"Early piribedil monotherapy of Parkinson's disease: a planned seven-month report of the REGAIN Study","volume":"21","author":"Rascol","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2740","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ana.10513","article-title":"Limitations of current Parkinson's disease therapy","volume":"53","author":"Rascol","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2745","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1517\/14656560902746041","article-title":"Rotigotine transdermal delivery for the treatment of Parkinson's disease","volume":"10","author":"Rascol","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2750","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.expneurol.2003.09.001","article-title":"Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia","volume":"185","author":"Ravenscroft","year":"2004","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2755","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1212\/01.wnl.0000268695.63392.10","article-title":"The impact of depressive symptoms in early Parkinson disease","volume":"69","author":"Ravina","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2760","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bbi.2008.07.003","article-title":"Peripheral cytokine profiles in Parkinson's disease","volume":"23","author":"Reale","year":"2009","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2765","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/mds.21803","article-title":"A systematic review of prevalence studies of depression in Parkinson's disease","volume":"23","author":"Reijnders","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2770","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/WNF.0b013e31815d25ce","article-title":"Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study","volume":"31","author":"Rektorova","year":"2008","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2775","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1046\/j.1468-1331.2003.00612.x","article-title":"Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study","volume":"10","author":"Rektorova","year":"2003","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2780","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1468-1331.2004.00966.x","article-title":"Cognitive performance in people with Parkinson's disease and mild or moderate depression: effects of dopamine agonists in an add-on to L-Dopa therapy","volume":"12","author":"Rektorova","year":"2005","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2785","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/brain\/awh445","article-title":"Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system","volume":"128","author":"Remy","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2790","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11910-007-0045-z","article-title":"Depression and apathy in Parkinson's disease","volume":"7","author":"Richard","year":"2007","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2795","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.parkreldis.2007.06.015","article-title":"Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease","volume":"13","author":"Riederer","year":"2007","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2800","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/sj.npp.1300954","article-title":"The alpha2-adrenoceptor antagonist dexefaroxan enhances hippocampal neurogenesis by increasing the survival and differentiation of new granule cells","volume":"31","author":"Rizk","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2805","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1093\/cercor\/bhm066","article-title":"Differential regulation of fronto-executive function by the monoamines and acetylcholine","volume":"17","author":"Robbins","year":"2007","journal-title":"Cereb Cortex"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2810","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1471-4159.2008.05588.x","article-title":"Intracellular signaling pathways involved in post-mitotic dopaminergic PC12 cell death induced by 6-hydroxydopamine","volume":"107","author":"Rodriguez-Blanco","year":"2008","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2815","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.neuroscience.2009.03.024","article-title":"Retrieval mediated by hippocampal extracellular signal-regulated kinase\/mitogen-activated protein kinase is required for memory strengthening","volume":"160","author":"Roesler","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2820","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1353-8020(03)00067-1","article-title":"Depression in Parkinson's disease: clinical correlates and outcome","volume":"10","author":"Rojo","year":"2003","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2825","doi-asserted-by":"crossref","first-page":"13804","DOI":"10.1073\/pnas.0702753104","article-title":"Norepinephrine loss produces more profound motor deficits than MPTP treatments in mice","volume":"104","author":"Rommelfanger","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2830","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.bcp.2007.01.036","article-title":"Norepinephrine: the redheaded stepchild of Parkinson's disease","volume":"74","author":"Rommelfanger","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2835","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1007\/BF00819564","article-title":"Indications of piribedil in L-DOPA-treated Parkinsonian patients: physiopathologic study","volume":"239","author":"Rondot","year":"1975","journal-title":"J Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2840","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/BF00819564","article-title":"Activity and acceptability of trivastal in Parkinson's disease: a multicenter study","volume":"239","author":"Rondot","year":"1992","journal-title":"J Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2845","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.pnpbp.2008.05.020","article-title":"Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice","volume":"32","author":"Rosa","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2850","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1093\/brain\/awn112","article-title":"Parkinson's disease and dopaminergic therapy\u2014differential effects on movement, reward and cognition","volume":"131","author":"Rowe","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2855","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1124\/mol.105.012153","article-title":"Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists","volume":"68","author":"Ryman-Rasmussen","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2860","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/mds.22519","article-title":"Genitourinary dysfunction in Parkinson's disease","volume":"25","author":"Sakakibara","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2865","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00213-006-0668-9","article-title":"Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits","volume":"191","author":"Salamone","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2870","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/j.parkreldis.2008.04.017","article-title":"Dopamine\/adenosine interactions related to locomotion and tremor in animal models: possible relevance to parkinsonism","volume":"14","author":"Salamone","year":"2008","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2875","first-page":"S47","article-title":"Piribedil in adjunction to L-Dopa in Parkinson's disease patients: a 9-month follow up","volume":"17","author":"Salazar","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2880","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/sj.mp.4000543","article-title":"Genetic alteration of the alpha2-adrenoceptor subtype C in mice affects the development of behavioral despair and stress-induced increases in plasma corticosterone levels","volume":"4","author":"Sallinen","year":"1999","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2885","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/sj.bjp.0707005","article-title":"Pharmacological characterization and CNS effects of a novel highly selective alpha2C-adrenoceptor antagonist JP-1302","volume":"150","author":"Sallinen","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2890","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1017\/S1355617700677056","article-title":"Theory of mind and executive functions in normal human aging and Parkinson's disease","volume":"6","author":"Saltzman","year":"2000","journal-title":"J Int Neuropsychol Soc"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2895","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0072-9752(07)83002-8","article-title":"Functional neurochemistry of the basal ganglia","volume":"83","author":"Samadi","year":"2007","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2900","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1365-2125.2007.02938.x","article-title":"Comparison of pramipexole with and without domperidone co-administration on alertness, autonomic, and endocrine functions in healthy volunteers","volume":"64","author":"Samuels","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2905","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2174\/157015908785777229","article-title":"Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function Part I: principles of functional organisation","volume":"6","author":"Samuels","year":"2008","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2910","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/157015908785777193","article-title":"Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function Part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans","volume":"6","author":"Samuels","year":"2008","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2915","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/sj.npp.1300418","article-title":"Addition of the alpha2-antagonist yohimbine to fluoxetine: effects on rate of antidepressant response","volume":"29","author":"Sanacora","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2920","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.nbd.2007.04.016","article-title":"In vivo evidence of D3 dopamine receptor sensitization in parkinsonian primates and rodents with L-DOPA-induced dyskinesias","volume":"27","author":"Sanchez-Pernaute","year":"2007","journal-title":"Neurobiol Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2925","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1002\/hbm.20642","article-title":"Single dose of a dopamine agonist impairs reinforcement learning in humans: evidence from event-related potentials and computational modeling of striatal-cortical function","volume":"30","author":"Santesso","year":"2009","journal-title":"Hum Brain Mapp"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2930","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1471-4159.2008.05831.x","article-title":"L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice","volume":"108","author":"Santini","year":"2009","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2935","doi-asserted-by":"crossref","first-page":"ra36","DOI":"10.1126\/scisignal.2000308","article-title":"Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia","volume":"2","author":"Santini","year":"2009","journal-title":"Sci Signal"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2940","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.1523\/JNEUROSCI.0852-07.2007","article-title":"Critical involvement of cAMP\/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia","volume":"27","author":"Santini","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2945","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nrn2573","article-title":"The locus coeruleus and noradrenergic modulation of cognition","volume":"10","author":"Sara","year":"2009","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2950","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1074-7427(03)00070-4","article-title":"Attentional functions of cortical cholinergic inputs: what does it mean for learning and memory?","volume":"80","author":"Sarter","year":"2003","journal-title":"Neurobiol Learn Mem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2955","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ng.485","article-title":"Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease","volume":"12","author":"Satake","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2960","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/00001756-199501000-00026","article-title":"A functional test identifies dopamine agonists selective for D3 vs D2 receptors","volume":"6","author":"Sautel","year":"1995","journal-title":"NeuroReport"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2965","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pneurobio.2009.01.009","article-title":"5-HT(1A) receptor function in major depressive disorder","volume":"88","author":"Savitz","year":"2009","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2970","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/mds.10464","article-title":"Fipamezole (JP-1730) is a potent \u03b12 adrenergic receptor antagonist that reduces Levo-Dopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease","volume":"18","author":"Savola","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2975","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1212\/01.wnl.0000257821.28992.db","article-title":"Cognitive slowing in Parkinson disease is accompanied by hypofunctioning of the striatum","volume":"68","author":"Sawamoto","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2980","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","article-title":"Dopamine agonists and the risk of cardiac-valve regurgitation","volume":"356","author":"Schade","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2985","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nrd2087","article-title":"Novel pharmacological targets for the treatment of Parkinson's disease","volume":"5","author":"Schapira","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2990","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1002\/ana.10514","article-title":"Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease","volume":"53","author":"Schapira","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb2995","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1016\/S0024-3205(01)01016-5","article-title":"Evaluation of the alpha2C-adrenoceptor as a neuropsychiatric drug target: studies in transgenic mouse models","volume":"68","author":"Scheinin","year":"2001","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3000","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00210-008-0341-4","article-title":"The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease","volume":"379","author":"Scheller","year":"2009","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3005","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/mds.20811","article-title":"Upregulation of dopamine D2 receptors in dopaminergic drug-naive patients with Parkin gene mutations","volume":"21","author":"Scherfler","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1353-8020(99)00051-6","article-title":"Parkinson's disease subtypes: clinical classification and ventricular cerebrospinal fluid analysis","volume":"6","author":"Schiess","year":"2000","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3015","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00702-008-0102-z","article-title":"Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements","volume":"115","author":"Schmidt","year":"2008","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3020","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/0006-8993(94)90471-5","article-title":"Effects of dihydrexidine, a full dopamine D1 receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys","volume":"663","author":"Schneider","year":"1994","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3025","first-page":"1522","article-title":"Psychological studies of a long-term treatment of the neurovascular syndrom with Trivastal","volume":"70","author":"Scholing","year":"1975","journal-title":"Med Klin"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3030","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1523\/JNEUROSCI.3463-05.2006","article-title":"The dopaminergic midbrain participates in human episodic memory formation: evidence from genetic imaging","volume":"26","author":"Schott","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3035","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1523\/JNEUROSCI.21-13-04875.2001","article-title":"The \u03b12A-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety","volume":"21","author":"Schramm","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3040","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1046\/j.1472-8206.2002.00070.x","article-title":"Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteers","volume":"16","author":"Sch\u00fcck","year":"2002","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3045","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0301-0082(96)00040-8","article-title":"The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments","volume":"50","author":"Schwarting","year":"1996","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2004.05.006","article-title":"The principal features and mechanisms of dopamine modulation in the prefrontal cortex","volume":"74","author":"Seamans","year":"2004","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3055","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1093\/brain\/awp234","article-title":"A clinico-pathological study of subtypes in Parkinson's disease","volume":"132","author":"Selikhova","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3060","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/JCP.0b013e3181a5233f","article-title":"Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis","volume":"29","author":"Serretti","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3065","doi-asserted-by":"crossref","first-page":"S521","DOI":"10.1002\/mds.22049","article-title":"Levodopa unresponsive symptoms in Parkinson disease","volume":"23","author":"Sethi","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3070","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00213-008-1250-4","article-title":"Inhibition of the norepinephrine transporter improves behavioral flexibility in rats and monkeys","volume":"202","author":"Seu","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3075","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0014-2999(89)90651-1","article-title":"Biochemical and functional studies on EMD 49 980: a potent, selectively presynaptic D2 dopamine agonist with actions on serotonin systems","volume":"160","author":"Seyfried","year":"1989","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3080","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.20861","article-title":"Crossroads in GDNF therapy for Parkinson's disease","volume":"21","author":"Sherer","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3085","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0893-133X(01)00400-6","article-title":"Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat","volume":"26","author":"Shirazi-Southall","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3090","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.bbr.2004.05.023","article-title":"The role of dopamine in cognitive sequence learning: evidence from Parkinson's disease","volume":"156","author":"Shohamy","year":"2005","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000117615","article-title":"Dopamine receptor stimulation in the treatment of depression: piribedil (ET-495)","volume":"4","author":"Shopsin","year":"1978","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3100","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s007020050171","article-title":"Parkinson's disease: a major hypokinetic basal ganglia disorder","volume":"106","author":"Sian","year":"1999","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3105","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0014-2999(97)01235-1","article-title":"Opposite effects of dopamine D2 and D3 receptors on learning and memory in the rat","volume":"336","author":"Sigala","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3110","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.expneurol.2004.03.022","article-title":"Selective blockade of D3 dopamine receptors enhances the antiparkinsonian properties of ropinirole and Levodopa in the MPTP-lesioned primate","volume":"188","author":"Silverdale","year":"2004","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3115","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.2174\/138161208784480072","article-title":"Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions","volume":"14","author":"Simola","year":"2008","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3120","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/mds.20400","article-title":"End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: a pharmacokinetic\/pharmacodynamic, randomized, double-blind study","volume":"20","author":"Simon","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3125","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000197103","article-title":"Treatment of early Parkinson's disease. Part 1","volume":"61","author":"Simuni","year":"2009","journal-title":"Eur Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3130","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1159\/000197104","article-title":"Treatment of early Parkinson's disease. Part 2","volume":"61","author":"Simuni","year":"2009","journal-title":"Eur Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3135","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00213-004-1809-7","article-title":"The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors","volume":"175","author":"Siuciak","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3140","doi-asserted-by":"crossref","first-page":"23059","DOI":"10.1074\/jbc.M000796200","article-title":"A four amino acid deletion polymorphism in the third intracellular loop of the human \u03b12C-adrenergic receptor confers impaired coupling to multiple effectors","volume":"275","author":"Small","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3145","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/mds.870110203","article-title":"An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated common marmosets","volume":"11","author":"Smith","year":"1996","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3150","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00002826-200005000-00002","article-title":"Transdermal administration of piribedil reverses MPTP-induced motor deficits in the common marmoset","volume":"23","author":"Smith","year":"2000","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3155","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/01.WNF.0000220818.71231.DF","article-title":"Switching from Levo-Dopa to the long-acting dopamine D2\/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates","volume":"29","author":"Smith","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3160","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0091-3057(98)00230-5","article-title":"The dopamine D3\/D2 receptor agonist 7-OH-DPAT induces cognitive impairment in the marmoset","volume":"63","author":"Smith","year":"1999","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3165","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/mds.10200","article-title":"Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation","volume":"17","author":"Smith","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3170","doi-asserted-by":"crossref","first-page":"S534","DOI":"10.1002\/mds.22027","article-title":"Striatal and extrastriatal dopamine in the basal ganglia: an overview of its anatomical organization in normal and parkinsonian brains","volume":"23","author":"Smith","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3175","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2174\/187152706784111551","article-title":"The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders","volume":"5","author":"Sokoloff","year":"2006","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3180","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1586\/14737175.8.12.1829","article-title":"What's in the pipeline for the treatment of Parkinson's disease","volume":"8","author":"Sommer","year":"2008","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3185","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1471-4159.2005.03094.x","article-title":"Mild prenatal protein malnutrition increases \u03b12C-adrenoceptor density in the cerebral cortex during postnatal life and impairs neocortical long-term potentiation and visuo-spatial performance in rats","volume":"93","author":"Soto-Moyano","year":"2005","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3190","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1046\/j.1460-9568.2003.02684.x","article-title":"Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats","volume":"17","author":"Srinivasan","year":"2003","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3195","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.bbr.2003.08.016","article-title":"Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease","volume":"151","author":"Srinivasan","year":"2004","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3200","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.bbr.2004.03.002","article-title":"Treatment with \u03b12-adrenoceptor antagonist, 2-methoxy idazoxan, protects against 6-hydroxydopamine-induced Parkinsonian symptoms in rats: neurochemical and behavioral evidence","volume":"154","author":"Srinivasan","year":"2004","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3205","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/NRL.0b013e31816606a7","article-title":"Impulse control disorders and pathological gambling in patients with Parkinson disease","volume":"14","author":"Stamey","year":"2008","journal-title":"Neurologist"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3210","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1176\/jnp.4.2.134","article-title":"Reliability, validity, and clinical correlates of apathy in Parkinson's disease","volume":"4","author":"Starkstein","year":"1992","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3215","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00702-008-0179-4","article-title":"Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: a systematic review","volume":"116","author":"Steiger","year":"2009","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3220","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.expneurol.2009.07.011","article-title":"Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction","volume":"219","author":"Stockwell","year":"2009","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3225","doi-asserted-by":"crossref","first-page":"S421","DOI":"10.1016\/S1353-8020(08)70041-5","article-title":"Positron emission tomography in premotor Parkinson's disease","volume":"13","author":"Stoessl","year":"2007","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3230","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1517\/14728222.12.4.425","article-title":"Potential therapeutic targets for Parkinson's disease. Expert. Opin. Ther. Targets for Parkinson's disease","volume":"12","author":"Stoessl","year":"2008","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3235","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0014-2999(99)00260-5","article-title":"Leads for the development of neuroprotective treatment in Parkinson's disease and brain imaging methods for estimating treatment efficacy","volume":"375","author":"Stoof","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3240","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1038\/sj.bjp.0707672","article-title":"Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors","volume":"153","author":"Strange","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3245","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.tins.2007.03.009","article-title":"Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease","volume":"30","author":"Sulzer","year":"2007","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3250","doi-asserted-by":"crossref","first-page":"6579","DOI":"10.1523\/JNEUROSCI.16-20-06579.1996","article-title":"Coordinated expression of dopamine receptors in neostriatal medium spiny neurons","volume":"16","author":"Surmeier","year":"1996","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3255","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0028-3932(99)00103-7","article-title":"Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication","volume":"38","author":"Swainson","year":"2000","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3260","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.conb.2004.04.001","article-title":"Mitogen-activated protein kinases in synaptic plasticity and memory","volume":"14","author":"Sweatt","year":"2004","journal-title":"Curr Opin Neurobiol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3265","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/cpt19741661077","article-title":"Piribedil, a dopamine agonist, in Parkinson's disease","volume":"16","author":"Sweet","year":"1974","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3270","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/sj.npp.1300877","article-title":"Heritable differences in the dopaminergic regulation of behavior in rats: relationship to D2-like receptor G-protein function","volume":"31","author":"Swerdlow","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3275","doi-asserted-by":"crossref","first-page":"12032","DOI":"10.1523\/JNEUROSCI.3446-08.2008","article-title":"Differential contributions of prefrontal and hippocampal dopamine D1 and D2 receptors in human cognitive functions","volume":"28","author":"Takahashi","year":"2008","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3280","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0006-8993(00)02493-8","article-title":"Increase of Bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinson drugs, talipexole and pramipexole","volume":"872","author":"Takata","year":"2000","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3285","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.neuropharm.2009.06.030","article-title":"Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides","volume":"58","author":"Tamim","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3290","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1046\/j.1472-8206.2003.00122.x","article-title":"Piribedil-induced sleep attacks in Parkinson's disease","volume":"17","author":"Tan","year":"2003","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3295","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1034\/j.1600-0404.2003.02104.x","article-title":"Piribedil and bromocriptine in Parkinson's disease: a single-blind crossover study","volume":"107","author":"Tan","year":"2003","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3300","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0361-9230(96)00026-3","article-title":"The effects of prefrontal intracortical microinjections of an \u03b12-agonist, \u03b12-antagonist and lidocaine on the delayed alternation performance of aged rats","volume":"40","author":"Tanila","year":"1996","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3305","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/mds.22960","article-title":"Pramipexole combined with Levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets","volume":"25","author":"Tarayani-Binazir","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3310","doi-asserted-by":"crossref","first-page":"8103","DOI":"10.1523\/JNEUROSCI.1495-09.2009","article-title":"Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity","volume":"29","author":"Taylor","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3675","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0306-4522(02)00535-3","article-title":"Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets","volume":"115","author":"Tel","year":"2002","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3315","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1046\/j.1471-4159.1997.68020778.x","article-title":"Acetylcholine release in the rat prefrontal cortex in vivo: modulation by \u03b12-adrenoceptor agonists and antagonists","volume":"68","author":"Tellez","year":"1997","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clinthera.2005.12.003","article-title":"Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease: a review of the literature","volume":"28","author":"Thobois","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3325","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/brain\/awq032","article-title":"Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation","volume":"133","author":"Thobois","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3330","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00213-009-1466-y","article-title":"Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety","volume":"204","author":"Thomas","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3335","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrn1346","article-title":"MAPK cascades signalling and synaptic plasticity","volume":"5","author":"Thomas","year":"2004","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3340","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/0269881105051529","article-title":"Selective effects of clonidine and temazepam on attention and memory","volume":"19","author":"Tiplady","year":"2005","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3345","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1124\/mol.104.003376","article-title":"Adenosine A2A receptor and dopamine D3 receptor interactions: evidence of functional A2A\/D3 heteromeric complexes","volume":"67","author":"Torvinen","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3350","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.pneurobio.2008.05.003","article-title":"Progress in Parkinson's disease\u2014where do we stand?","volume":"85","author":"Toulouse","year":"2008","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3355","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1124\/mol.104.007864","article-title":"The neurotransmitter noradrenaline rescues septal cholinergic neurons in culture from degeneration caused by low-level oxidative stress","volume":"67","author":"Traver","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3360","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1046\/j.1471-4159.2001.00556.x","article-title":"Noradrenaline provides long-term protection to dopaminergic neurons by reducing oxidative stress","volume":"79","author":"Troadec","year":"2001","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3365","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1586\/ern.09.50","article-title":"Recognition and management of Parkinson's disease during the premotor (prodromal) phase","volume":"9","author":"Truong","year":"2009","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3370","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1124\/jpet.106.109207","article-title":"The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease","volume":"319","author":"Turle-Lorenzo","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3375","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2165\/00023210-199605050-00006","article-title":"Comparative review of dopamine receptor agonists in Parkinson's disease","volume":"5","author":"Uitti","year":"1996","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3380","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3181\/0707-MR-193","article-title":"Current management of the cognitive dysfunction in Parkinson's disease: how far have we come?","volume":"233","author":"Vale","year":"2008","journal-title":"Exp Biol Med"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3385","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1111\/j.1460-9568.2004.03278.x","article-title":"Addictive and non-addictive drugs induce distinct and specific patterns of ERK activation in mouse brain","volume":"19","author":"Valjent","year":"2004","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3390","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1523\/JNEUROSCI.0837-06.2006","article-title":"Dopamine D3 receptor agonist delivery to a model of Parkinson's disease restores the nigrostriatal pathway and improves locomotor behavior","volume":"26","author":"Van Kampen","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3395","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1111\/j.1471-4159.2007.04650.x","article-title":"Differential signaling of dopamine D2S and D2L receptors to inhibit ERK1\/2 phosphorylation","volume":"102","author":"Van-Ham","year":"2007","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3400","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.pbb.2008.04.010","article-title":"A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and Levodopa-induced dyskinesias in a monkey model","volume":"90","author":"Vanover","year":"2008","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3405","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/mds.22453","article-title":"Psychotic and compulsive symptoms in Parkinson's disease","volume":"24","author":"Verbaan","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3410","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.pbb.2006.02.015","article-title":"The adrenergic \u03b12-receptor and sexual incentive motivation in male rats","volume":"83","author":"Viitamaa","year":"2006","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3415","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.nbd.2008.11.010","article-title":"Dopamine D3 receptor stimulation underlies the development of L-Dopa-induced dyskinesia in animal models of Parkinson's disease","volume":"35","author":"Visanji","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3420","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.expneurol.2006.05.016","article-title":"Actions at sites other than D3 receptors mediate the effects of BP897 on L-dopa-induced hyperactivity in monoamine-depleted rats","volume":"202","author":"Visanji","year":"2006","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3425","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1176\/ajp.157.1.75","article-title":"Association between age-related decline in brain dopamine activity and impairment in frontal and cingulate metabolism","volume":"157","author":"Volkow","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3430","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1254\/jphs.09R02CR","article-title":"Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3\u03b2, \u03b2-catenin, and neurotrophin cascades","volume":"110","author":"Wada","year":"2009","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3435","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1124\/mol.56.5.1005","article-title":"Gi activator region of \u03b12A-adrenergic receptors: distinct basic residues mediate Gi versus GS activation","volume":"56","author":"Wade","year":"1999","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3440","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1471-4159.2005.03055.x","article-title":"Dopamine D2 receptor stimulation of mitogen-activated protein kinases mediated by cell type-dependent transactivation of receptor tyrosine kinases","volume":"93","author":"Wang","year":"2005","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3445","doi-asserted-by":"crossref","first-page":"25948","DOI":"10.1074\/jbc.M605415200","article-title":"Arrestin serves as a molecular switch, linking endogenous \u03b12-adrenergic receptors to SRC-dependent, but not SRC-independent, ERK activation","volume":"281","author":"Wang","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3450","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2007.03.015","article-title":"\u03b12A-Adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex","volume":"129","author":"Wang","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3455","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1212\/01.wnl.0000252355.79284.22","article-title":"Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease","volume":"68","author":"Watts","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3460","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00008877-199501000-00012","article-title":"A double-blind cross-over placebo-controlled trial of the effects of bromocriptine on psychomotor function, cognition, and mood in de novo patients with Parkinson's disease","volume":"6","author":"Weddell","year":"1995","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3465","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/1531-8257(199909)14:5<716::AID-MDS1002>3.0.CO;2-Q","article-title":"The initial treatment of Parkinson's disease should begin with Levodopa","volume":"14","author":"Weiner","year":"1999","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3470","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1001\/archneur.65.6.705","article-title":"There is no Parkinson disease","volume":"65","author":"Weiner","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3475","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1002\/ana.21454","article-title":"Dopamine and impulse control disorders in Parkinson's disease","volume":"64","author":"Weintraub","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3480","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.parkreldis.2006.03.006","article-title":"Frequency and correlates of co-morbid psychosis and depression in Parkinson's disease","volume":"12","author":"Weintraub","year":"2006","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3485","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1046\/j.1471-4159.1998.70052139.x","article-title":"Activation of microtubule-associated protein kinase (Erk) and p70 S6 kinase by D2 dopamine receptors","volume":"70","author":"Welsh","year":"1998","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3490","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1136\/bmj.324.7352.1508","article-title":"Evaluating drug treatments for Parkinson's disease: how good are the trials?","volume":"324","author":"Wheatley","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3495","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ana.10609","article-title":"Slower progression of Parkinson's disease with ropinirole versus Levodopa: the REAL-PET study","volume":"54","author":"Whone","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3500","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.neuroscience.2005.09.028","article-title":"Under the curve: critical issues for elucidating D1 receptor function in working memory","volume":"139","author":"Williams","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3505","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1093\/brain\/awp245","article-title":"The distinct cognitive syndromes of Parkinson's disease: 5year follow-up of the CamPalGN cohort","volume":"132","author":"Williams-Gray","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3510","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00023210-200620060-00004","article-title":"Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options","volume":"20","author":"Williams-Gray","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3515","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1515\/REVNEURO.2004.15.1.75","article-title":"The implementation of acute versus chronic animal models for treatment discovery in Parkinson's disease","volume":"15","author":"Willis","year":"2004","journal-title":"Rev Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3520","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1097\/00004850-199707003-00002","article-title":"The mesolimbic dopamine system as a target for rapid antidepressant action","volume":"12","author":"Willner","year":"1997","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3525","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/BF02245626","article-title":"Cholinergic modulation of a decrement in social investigation following repeated contacts between mice","volume":"121","author":"Winslow","year":"1995","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3530","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.neubiorev.2008.04.004","article-title":"Object recognition memory: neurobiological mechanisms of encoding, consolidation and retrieval","volume":"32","author":"Winters","year":"2008","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3535","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF03033808","article-title":"Dopamine and reward: the anhedonia hypothesis 30years on","volume":"14","author":"Wise","year":"2008","journal-title":"Neurotox Res"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3540","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1042\/bj3210721","article-title":"Interactions of the \u03b12A-adrenoceptor with multiple G-family G-proteins: studies with pertussis toxin-resistant G-protein mutants","volume":"321","author":"Wise","year":"1997","journal-title":"Biochem J"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3545","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1176\/jnp.2006.18.3.397","article-title":"Differential effects of L-Dopa and subthalamic stimulation on depressive symptoms and hedonic tone in Parkinson's disease","volume":"18","author":"Witt","year":"2006","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3550","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(08)70114-5","article-title":"Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study","volume":"7","author":"Witt","year":"2008","journal-title":"Neurol Lancet"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3555","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1471-4159.2009.06414.x","article-title":"Glycogen synthase kinase 3\u03b2 in the nucleus accumbens core mediates cocaine-induced behavioral sensitization","volume":"111","author":"Xu","year":"2009","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3560","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1586\/14737175.8.4.671","article-title":"Dopamine agonists in Parkinson's disease","volume":"8","author":"Yamamoto","year":"2008","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3565","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/mds.22036","article-title":"The frequency of cardiac valvular regurgitation in Parkinson's disease","volume":"23","author":"Yamashiro","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3570","doi-asserted-by":"crossref","first-page":"11607","DOI":"10.1073\/pnas.96.20.11607","article-title":"D2 dopamine receptors induce mitogen-activated protein kinase and cAMP response element-binding protein phosphorylation in neurons","volume":"96","author":"Yan","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3575","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0014-2999(97)01375-7","article-title":"\u03b12-Adrenergic control of dopamine overflow and metabolism in mouse striatum","volume":"339","author":"Yavich","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3580","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0014-2999(03)01324-4","article-title":"Atipamezole, an \u03b12-adrenoceptor antagonist, augments the effects of L-Dopa on evoked dopamine release in rat striatum","volume":"462","author":"Yavich","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3585","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1358\/dot.2005.41.6.893613","article-title":"Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline","volume":"41","author":"Youdim","year":"2005","journal-title":"Drugs Today"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3590","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/mds.22441","article-title":"Examination of the Lille apathy rating scale in Parkinson disease","volume":"24","author":"Zahodne","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3595","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3600","doi-asserted-by":"crossref","first-page":"35842","DOI":"10.1074\/jbc.M611758200","article-title":"Regulation of dopamine transporter function and cell surface expression by D3 dopamine receptors","volume":"282","author":"Zapata","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3605","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1358\/dot.2006.42.1.932510","article-title":"Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease","volume":"42","author":"Zareba","year":"2006","journal-title":"Drugs Today"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3610","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archneur.60.3.337","article-title":"Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases","volume":"60","author":"Zarow","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3615","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0014-2999(02)02497-4","article-title":"Effects of \u03b1-adrenoceptor agonists and antagonists on histamine-induced impairment of memory retention of passive avoidance learning in rats","volume":"454","author":"Zarrindast","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3620","first-page":"263","article-title":"ACTH 4\u20139 analogue facilitates the anti-immobility effect of antidepressants and dopamine agonists in swimming rats","volume":"48","author":"Zebrowska-Lupina","year":"1997","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3625","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1080\/13803390500246910","article-title":"An examination of executive dysfunction associated with frontostriatal circuitry in Parkinson's disease","volume":"28","author":"Zgaljardic","year":"2006","journal-title":"J Clin Exp Neuropsychol"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3630","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00702-004-0178-z","article-title":"Cognitive and behavioral dysfunction in Parkinson's disease: neurochemical and clinicopathological contributions","volume":"111","author":"Zgaljardic","year":"2004","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3635","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1523\/JNEUROSCI.0060-04.2004","article-title":"Cocaine-induced intracellular signaling and gene expression are oppositely regulated by the dopamine D1 and D3 receptors","volume":"24","author":"Zhang","year":"2004","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3640","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0169-328X(03)00026-3","article-title":"The \u03b12C-adrenoceptor modulates GABA release in mouse striatum","volume":"112","author":"Zhang","year":"2003","journal-title":"Mol Brain Res"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3645","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/npp.2008.184","article-title":"Postsynaptic \u03b12-adrenergic receptors are critical for the antidepressant-like effects of desipramine on behavior","volume":"34","author":"Zhang","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3650","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/sj.npp.1300680","article-title":"Repeated cocaine administration induces gene expression changes through the dopamine D1 receptors","volume":"30","author":"Zhang","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3655","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/mds.10359","article-title":"Efficacy of piribedil as early combination to Levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study","volume":"18","author":"Ziegler","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2010.06.002_bb3660","first-page":"1414","article-title":"Action of piribedil in Parkinson disease. Multicenter study","volume":"28","author":"Ziegler","year":"1999","journal-title":"Presse M\u00e9d"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725810001208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725810001208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T14:05:18Z","timestamp":1740233118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725810001208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":733,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0163725810001208"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2010.06.002","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}